Methusalem Report 2011

Transcription

Methusalem Report 2011 University of Antwerp Centre of Excellence: Vaccine & Infectious Disease Institute VAXINFECTIO Hasselt University Center for Statistics CenStat - Table of Contents -
© VAXINFECTIO & CenStat, 2012 Author: Vanessa Vankerckhoven 2
- Methusalem Report 2011 -
TableofContents
1 Methusalem Consortium ............................................................................................................................... 9 1.1 Composition of the Methusalem Consortium ....................................................................................... 9 1.2 Organisational structure of the Methusalem Consortium .................................................................. 11 1.3 Management structure of the Methusalem Consortium .................................................................... 14 1.4 The Methusalem Consortium within the University of Antwerp & Hasselt University ....................... 15 Vaxinfectio as formal Institute within the Faculty of Medicine (UA) .......................................................... 15 The Center for Statistics at the Faculty of Sciences (UHasselt) ................................................................... 15 2 Objectives of the Methusalem Consortium................................................................................................. 17 3 Research Activities 2011 .............................................................................................................................. 19 4 Dissemination and Communication Activities ............................................................................................. 23 5 6 7 8 4.1 Scientific papers in peer reviewed journals ......................................................................................... 23 4.2 Methusalem Research Days ................................................................................................................ 23 4.3 Scientific Chair in Evidence Based Vaccinology ................................................................................... 23 4.4 Website ................................................................................................................................................ 24 Valorisation .................................................................................................................................................. 27 5.1 Role of IOF Managers .......................................................................................................................... 27 5.2 Collaboration with industry ................................................................................................................. 27 5.3 Strategic National and International Collaborations with other research groups & academia .......... 27 5.4 Flanders Vaccine .................................................................................................................................. 28 External Research Funding .......................................................................................................................... 29 6.1 Overview of submitted projects 2011 ................................................................................................. 29 6.2 Overview of granted projects 2007‐2011 ............................................................................................ 35 6.3 Project proposals in the pipeline 2012 ................................................................................................ 36 6.4 Difficulties encountered with obtaining additional funding ................................................................ 43 Human Resources ........................................................................................................................................ 45 7.1 Overview of Methusalem Personnel ................................................................................................... 45 7.2 Opportunities for Postdoctoral Researchers ....................................................................................... 46 7.3 PhD students & PhDs obtained............................................................................................................ 46 Budget & Investments ................................................................................................................................. 49 3
- Table of Contents -
8.1 Overall budget 2008‐2014 ................................................................................................................... 49 8.2 Budget Vaxinfectio .............................................................................................................................. 49 Investments in expert personnel 2011 ........................................................................................................ 49 Investments in state‐of‐the‐art technologies, methodologies and equipment 2011 ................................. 49 Future Investments in state‐of‐the‐art technologies, methodologies and equipment ............................... 50 8.3 Budget CenStat .................................................................................................................................... 50 Investments in expert personnel 2008‐2011 ............................................................................................... 51 Future Investments ..................................................................................................................................... 51 9 Annexes ....................................................................................................................................................... 53 ANNEX I: Administrative Information ............................................................................................................... 55 ANNEX II: Minutes of the meeting of the Board of Directors .......................................................................... 57 ANNEX III: List of joint peer‐reviewed Papers 2011 ......................................................................................... 61 ANNEX IV: Programme of the Methusalem Research Day n°4 (2012) ............................................................. 63 ANNEX V: Extracts of the Flemish Government Directive ................................................................................ 65 ANNEX VI: Personnel list anno 2011 ................................................................................................................ 73 ANNEX VII: List of ongoing Projects 2011 ......................................................................................................... 77 4
ExecutiveSummary
The Methusalem Consortium is an interuniversity collaboration between the Vaccine & Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp and the Centre for Statistics (CenStat) at Hasselt University. The Methusalem report 2011 is composed of 9 chapters. The format has changed significantly compared to the previous years and is now entirely focused on the activities, resources and output of the Methusalem Consortium as such. Chapter 1 describes the Methusalem consortium at the University of Antwerp and Hasselt University with their leading researchers and post‐doctoral researchers. The composition of the Board of Directors, responsible for the scientific management of the Methusalem consortium, and the Board of Advisors is presented. Furthermore, Annex I provides administrative information on the main contact persons, whereas in Annex II the minutes of the annual Board of Directors meeting held in January 2012 are given. Finally, embedding of the Methusalem consortium at both universities in terms of visibility and use of facilities is discussed. Chapter 2 provides an overview of the objectives of the Methusalem consortium. The consortium basically aims to study microbiological, immunological, mathematical‐biological, statistical, economical, societal and epidemiological aspects of infectious diseases and vaccines. In Chapter 3, a large table (Table 3.1) summarizes the ongoing research activities for which collaboration between Vaxinfectio and CenStat has been established. In 2011, 16 basic research questions and sub‐questions were addressed and translated into clinical research and basic research. For a large number of these research topics manuscripts have been published, submitted or are in preparation. Chapter 4 offers an overview of the dissemination and communication activities in 2011. Compared to 2010 the number of joint publications almost doubled (from 12 in 2010 to 21 in 2011). A detailed overview of the joint publications is listed in Annex III. In 2011, a dedicated Methusalem website has been set‐up and can be accessed through www.ua.ac.be/methusalem/vaxinfectio‐censtat. Each year the consortium organizes the "Methusalem Research Day" during which ongoing collaborative research between Vaxinfectio and CenStat is presented in order to stimulate further intra‐
consortium collaboration. At the fourth edition Prof Kourilsky (Institut Pasteur, France) gave a key note on ‘Systems Immonology’. The programme of the fourth Methusalem Research Day can be found in Annex IV. Chapter 5 covers the valorisation of scientific work, which is an important aspect for the Methusalem Consortium. Two dedicated staff members, one at Vaxinfectio and one at CenStat, are reponsible for all activities related to technology transfer and intellectual property rights. Collaboration opportunities with academia and industry are discussed in this chapter. In summary, the Methusalem consortium collaborates with Flemish and Walloon universities, research institutes and industrial partners based in Flanders and Belgium. Secondly, the consortium has built a worldwide network of scientific and industrial partners in over 50 countries. Also activities initiated by "Flanders Vaccine", a platform that aims to bring together expertise from academia and industry in the field of vaccine related research, to identify hurdles in the vaccination sector and to stimulate networking, are presented. Chapter 6 clearly shows the impressive number of external funding applications at national, European and international level. Over 150 projects are ongoing in 2011. Figures 6.1‐6.2 give an overview of the granted projects for the period 2007‐2011 either summarizing the number of projects split by type of funding or summarizing the obtained budget split by type of funding. Both the number of granted projects as well as the obtained budget increased considerably compared to the previous years. A detailed overview of ongoing projects can be found in Annex VII. Chapter 8 addresses the human resources management pursued by the consortium. Currently, the Methusalem consortium groups 134 staff members of which the majority are PhD students (n=61). Importantly, over 80% of these are being paid by external funding. It is expected that 23 PhDs will be 5
- Executive Summary -
finalised within the forthcoming 2 years. Interestingly, more than half (56%) of the staff members are women, which clearly indicates the efforts made by the consortium in terms of gender equality. Also, career opportunities and perspectives for young and more established researchers are considered very important and the management of the Methusalem consortium tries to offer as much career perspective as possible. However, without additional funding and career perspectives offered by the University management, sufficient long‐term perspectives for postdoctoral staff cannot be guaranteed. Annex VI lists the Methusalem staff members and their affiliation. Chapter 9 covers the Methusalem budget and investments. The Methusalem budget amounts to €5.179.619 for the period 2008‐2014 and is divided between the University of Antwerp (Vaxinfectio) and Hasselt University (CenStat; ratio 3:1). Both Vaxinfectio and CenStat mainly invest this budget in expert personnel, state of the art technologies, methodologies and equipment. In conclusion, the Methusalem consortium is a multdisciplinary consortium employing 134 staff members in 2011 of which 61 PhDs students. The consortium has published 21 joint Vaxinfectio‐
CenStat peer‐reviewed papers in 2011. The consortium organizes annual research days attracting a large number of scientists, also from outside the Methusalem consortium. An impressive number of externally funded projects were awarded in 2011. Over 150 project proposals are ongoing which generated more than €M30 of external funding. Nonetheless, the Methusalem consortium lacks mid‐
level postdoctoral researchers and (research) professorships leading to possible discontinuity of research and overstretching/overdemanding of existing staff. Future opportunities for the Methusalem Consortium comprise further expansion of the collaboration Vaxinfectio‐CenStat, set‐up of joint PhD theses, joint research projects and joint valorisation opportunities. Also, a further increase of the number of joint high‐level peer‐reviewed papers is envisioned by building on complementary expertises available within the Consortium. For more detailed information on Vaxinfectio and CenStat, we refer to the respective separate annual reports. 6
MethusalemKeyFeatures(SWOTanalysis)
Strengths  Multidisciplinary Consortium covering Vaccines, Infectious Diseases and Biostatistics as well as expertise in health economics, stem cell research and primary, secondary and tertiary care  The Methusalem Consortium employs 134 staff members of which 61 PhD students  Increasing number of joint publications since 2008 (21 in 2011)  Organisation of annual Methusalem Research Days  Over 150 projects ongoing in 2011.  More than €M30 of external funding obtained in 2011  Large number of EU‐funded projects  Large number of industrial collaborations and industry‐funded projects  Large number of national and international collaborations (over 50 countries) Weaknesses  Too few joint research projects  Too few joint valorisation efforts Opportunities  Further expansion of the collaboration Vaxinfectio‐CenStat  Set‐up of joint PhD theses  Set‐up of joint research projects  Increasing number of joint high‐level peer‐reviewed papers  Joint valorisation opportunities  Building on complementary expertises available within the Consortium  Organisation of courses on biostatistics  Organisation of networking events Threats  Future of Methusalem Funding  Too few permanent staff employed jeopardizing future FP7, DG Sanco and other EU grant applications  Lack of mid‐level (permanent) postdoctoral researchers leading to discontinuity of research  Lack of (research) professorships at the Faculty of Medicine, University of Antwerp  Lack of opportunity to be assigned as core facilities by the University of Antwerp  Incompatibility of Methusalem Funding with other BOF Funding at the University of Antwerp  Lack of efficient business units for joint research and projects) at the University of Antwerp 7
- Methusalem Key Features -
8
1 MethusalemConsortium
1.1 CompositionoftheMethusalemConsortium
The Methusalem Consortium is an interuniversity collaboration between:  The Vaccine & Infectious Disease Institute ‐ Vaxinfectio, University of Antwerp  The Centre for Statistics ‐ CenStat, Hasselt University 9
- Methusalem Consortium -
UNIVERSITY of ANTWERP Methusalem Team leader: Prof. Dr. Herman Goossens Research Unit: University of Antwerp, Vaccine & Infectious Disease Institute: VAXINFECTIO Chair: Prof Dr. Pierre Van Damme Vice‐chairs: Prof. Dr. Herman Goossens & Prof. Dr. Zwi Berneman Research & Innovation Manager (IOF): Dr. Vanessa Vankerckhoven Administrative coordinator: Gino Verwimp Administrative staff: Emmy Engelen & Sophie Nys Participating Research Units in the Institute: 1) Centre for the Evaluation of Vaccination (CEV), Faculty of Medicine. Head: Pierre Van Damme (100% ZAP) ‐ Koen Van Herck (10% ZAP) ‐ Heidi Theeten (100% postdoc BAP) – as from 1/6/2011 Collaborating unit: Research Unit Health Economics and Mathematical Modelling of Infectious Diseases (CHERMID) Head: Philippe Beutels (100% ZAPBOF) ‐ Niel Hens (50% ZAP) ‐ Olivier Lejeune (100% postdoc BAP) ‐ end 28/2/2011 ‐ Mathieu Andraud (100% postdoc BAP) ‐ Joke Bilcke (100% postdoc BAP) – as from 1/12/2011 2) Laboratory of Medical Microbiology, Faculty of Medicine. Head: Herman Goossens (100% ZAP) ‐ Greet Ieven (10% ZAP) ‐ Surbhi Malhotra (100% ZAPBOF) ‐ Katherine Loens (80% postdoc BAP) ‐ Pieter Moons (100% postdoc BAP) – as from 1/9/2011 Collaborating unit: Research Unit Infectious Diseases (RUID) Head: Samuel Coenen (30% ZAP, 70% BAP Research Leader) ‐ Sibyl Anthierens (80% postdoc BAP) 3) Laboratory of Experimental Hematology (LEH), Faculty of Medicine. Head: Zwi Berneman (100% ZAP) ‐ Peter Ponsaerts (100% postdoc BAP) ‐ Wilfried Schroyens (10% ZAP) ‐ Nathalie Cools (100% postdoc BAP) ‐ Katrien Vermeulen (100% postdoc BAP) Collaborating unit: Centre for Cell Therapy and Regenerative Medicine (CCRM), University Hospital Antwerp (UZA) Head: Viggo Van Tendeloo (100% ZAPBOF) ‐ Evelien Smits (100% postdoc BAP) ‐ Eva Lion (100% postdoc BAP) 10
HASSELT UNIVERSITY Methusalem Team leader: Prof. Dr. Geert Molenberghs Research Unit: Center for Statistics (CenStat), Faculty of Sciences. Head: Geert Molenberghs (100% ZAP) - Marc Aerts (100% ZAP) - Christel Faes (100% ZAP) - Niel Hens (50% ZAP) - Nele Goeyvaerts (100% postdoc BAP) 1.2 OrganisationalstructureoftheMethusalemConsortium
Centre for the Evaluation of Vaccination 11
Laboratory of Medical Microbiology 12
Laboratory of Experimental Hematology Censtat Permanent staff members at I‐Biostat. For more information about the PhD students and other faculty staff please consult the list of CenStat members (Annex VI). 13
1.3 ManagementstructureoftheMethusalemConsortium
Director: Prof. Dr. Herman Goossens Board of Directors: Chair: H. Goossens, Vice‐chair: G. Molenberghs Composed of the heads of the 4 participating core research groups, the (part‐time) ZAP members (9), all postdocs (13), Research & Innovation Manager, administrative coordinator, one administrative officer Department of Research (ADOC) and the chairman of the Research Council. Total: 28 members. Meeting frequency: at least once per year Composition per (per 01/10/2011): Present number: 31 Goossens Herman, Chair and Head LMM (UA) Molenberghs Geert, Vice‐chair and Head CenStat (UH) Van Damme Pierre, Head CEV (UA) Berneman Zwi, Head LEH (UA) Vankerckhoven Vanessa, Research & Innovation Manager (IOF) – (UA) Verwimp Gino, Administrative coordinator (UA) Spruyt Eric , Head Department of Research, ADOC (UA) Peters Ann, Head Research Coordination (UH) Timmermans Jean‐Pierre, Chairman Research Council (UA) Janssen Paul, Chairman Research Council (UH) Aerts Marc (100% ZAP) (UH) Beutels Philippe (100% ZAPBOF) (UA) Faes Christel (100% ZAP) (UH) Hens Niel (100% ZAP) (UA/UH) Malhotra Surbhi (100% ZAPBOF) (UA) Van Tendeloo Viggo (100% ZAPBOF) (UA) Coenen Samuel (30% ZAP) (UA) Ieven Greet (10% ZAP) (UA) Ponsaerts Peter (10% ZAP) (UA) Schroyens Wilfried (10% ZAP) (UA) Van Herck Koen (10% ZAP) (UA) Andraud Mathieu (100% postdoc BAP) (UA) Anthierens Sibyl (80% postdoc BAP) (UA) Bilcke Joke (100% postdoc BAP) (UA) Cools Nathalie (100% postdoc BAP) (UA) Goeyvaerts Nele (100% postdoc BAP) (UH) Lion Eva (100% postdoc BAP) (UA) Loens Katherine (80% postdoc BAP) (UA) Moons Pieter (100% postdoc BAP) (UA) Smits Evelien (100% postdoc BAP) (UA) Theeten Heidi (100% postdoc BAP) (UA) 14
Vermeulen Katrien (100% postdoc BAP) (UA) Board of Advisors: Chair: H. Goossens Composed of one administrative member ADOC and researchers with international recognition in the research field:  Haruo Sugiyama, MD, PhD, Professor, Department of Functional Diagnostic Science Osaka University Graduate School of Medicine 1‐7, Yamada‐Oka, Suita City Osaka, Japan (confirmed);  Ron Dagan, Professor of Pediatrics and Infectious Diseases, Ben Gurion University, and director of the pediatric infectious disease unit of Soroka University Medical Center and at Ben Gurion University, Beer‐Sheva, Israel (confirmed)  Christopher C Butler, Professor and Head of Primary Care Medicine, Centre for Health Sciences Research, School of Medicine, Cardiff University (confirmed) Meeting frequency: at least once per year 1.4 The Methusalem Consortium within the University of Antwerp &
HasseltUniversity
VaxinfectioasformalInstitutewithintheFacultyofMedicine(UA)
The Vaccine & Infectious Disease Institute (VAXINFECTIO) was established as a formal Institute of the Faculty of Medicine of the University of Antwerp in 2007 to promote the multidisciplinary research of vaccines and infectious diseases. Since January 2008 VAXINFECTIO is formally recognised as Centre of Excellence of the University of Antwerp with Methusalem funding and since September 2010 it is formally recognized as WHO Collaborating Centre for Vaccines and Infectious Diseases. As from October 2009, all staff members of the Institute belong to the Department Vaxinfectio within the Faculty of Medicine. Within this unit, sub‐units have been formed, based on the specific research units composing the department and their leading researchers:  Vaxinfectio‐Laboratory of Medical Microbiology (lead by Prof. Dr. Herman Goossens)  Vaxinfectio‐Center for Evaluation of Vaccination (lead by Prof. Dr. Pierre Van Damme)  Vaxinfectio‐Laboratory of Experimental Hematology (lead by Prof. Dr. Zwi Berneman) VAXINFECTIO is aimed at integrated vaccine and microbiological research with a focus on increasing the understanding of the immune response in prophylactic and therapeutic vaccines (including tumour vaccines) and on the containment of antibiotic resistance. TheCenterforStatisticsattheFacultyofSciences(UHasselt)
The Center for Statistics at Hasselt University (former Limburgs Universitair Centrum) was founded in May 1998 as a result of a growing applied statistics branch within the university. The scientific research conducted within the Center for Statistics (CenStat) is internationally renowned, both for its theoretical as well as for its applied component. Also the education and consultancy records are excellent. Over the years CenStat has collaborated with many (inter)national institutions within and outside UHasselt, of which a fruitful collaboration of more than a decade with CEV, UA and with the other Vaxinfectio groups has led to its participation in the Methusalem Consortium. The Methusalem funding enables joining the expertise of Vaxinfectio and CenStat on a long term basis with shared appointments, enabling the consortium to play a pivotal role internationally. An ideal setting of what could become a more structural collaboration such as given by the unification of CenStat, UHasselt and the Biostatistical Centre at the Catholic University of Leuven in the Interuniversity Institute of Biostatistics and statistical Bioinformatics (I‐Biostat), anno 2008, strengthening both centres’ expertise in biostatistics, epidemiology and public health methodology, mathematical statistics and bioinformatics. 15
16
2 ObjectivesoftheMethusalemConsortium
The main basic research aim of the Consortium is to study microbiological, immunological, mathematical‐biological, statistical, economical, societal and epidemiological aspects of infectious diseases and vaccines. The constituting research teams of the Consortium will use the Methusalem funding to create a science platform with an aim (1) To structure and consolidate the existing pool of knowledge and expertise in their respective disciplines with targeted investments in qualified personnel, state‐of‐the‐art equipment and sufficient operational resources, and (2) To advance knowledge and expertise in the listed scientific fields with focus on multidisciplinarity and based on the highest quality standards, with a view to attract additional resources and to increase its scientific output. 17
- Objectives of the Methusalem Consortium -
18
3 ResearchActivities2011
Figure 3.1: dynamics of the research within the Methusalem Consortium Table 3.1 Overview of ongoing joint research activities BASIC QUESTION CLINICAL RESEARCH
BASIC RESEARCH
A 1. Correlation of humoral and cellular response in vaccinees? Correlation with protection? 1. Vaccine studies CEV 2. Duration of cell‐
mediated immunological (CMI) responses? 3. Immune tolerance mechanisms in infectious agents and tumours? 2. Long‐term follow‐up studies CEV 3. Phase I therapeutic DC vaccines in tumour, HIV and CMV patients 1. Analyzing vaccine‐
induced T cell responses by multi‐parametric flow cytometry and in vitro restimulation cytokine assays 2. Modelling vaccine‐
induced cellular responses as a function of time PARTNERS INVOLVED CEV, LEH, CenStat STATUS
LMM, LEH, CenStat Ongoing
Ongoing
3. in vitro studies of dendritic cells and their interation on suppressor T‐
cells B C 4. Mechanisms in non‐
4. Vaccine trials CEV response to vaccination (hepatitis B, influenza) 5. Immunoscence 5. Low influenza vaccine response in elderly 1. Role of TLR 1. Therapeutic DC stimulation in innate vaccine trials and adaptive immunity to microbes and tumours? 2. Role of TLR signalling and the immune modulatory effects of probiotic lactobacilli 1. Impact of 1. oropharyngeal vaccination on carriage in (family pneumococcal contacts of) infants carriage? during first year of life 4. Analyzing genetic factors in non‐responders 5. Analysis of the impact of CMV infection on the immune system of elderly 1. Effect of in vitro TLR3 signalling on the induction of antiviral and anti‐
tumoural T cell responses. 2. Measuring TLR signalling and effect of probiotics on signalling, on transfected cell lines and by ELISA. 1. & 2. Quantification of pneumococcal carriage, serotyping by Quellung reaction, strain typing by Manuscript in preparation CEV, LMM, CenStat Ongoing
19
- Research Activities 2011 -
BASIC QUESTION CLINICAL RESEARCH
BASIC RESEARCH
2. Impact of vaccination programmes on epidemiology of Hib, rotavirus, pertussis and meningococcus Effect of using new injection devices, adapted administration route and/or new adjuvant formula on vaccine efficacy? 1. Local immune response in vaccinees? 2. HPV identification in urine 2. (molecular) epidemiology in (family contacts of) infants during first year of life multilocus sequence typing, and antibiotic resistance profiling by disk diffusion, PCR and sequencing. Phase I trials using new injection devices, new administration routes or new adjuvants with existing vaccines 1. Phase I HPV trial
D E F G H 20
1. Neonatal/infant immunity? Impact of maternal antibodies? 2. Use of urine for HPV screening as diagnostic or for public health purposes 1. Longitudinal studies in pregnant women and their infants 2. Changes in the intestinal microbiotome of infants with asthma and effect of prebiotics on the development of asthma? 2. Double blind placebo controlled intervention study on 200 neonates 3. Differences in the microbiotome of infants with obesity vs non‐obesity 3. Pilot study in 60 infants 4. Physical activity in obese and non‐obese children Kinetics of cellular‐
mediated immunity to varicella zoster virus after contact with a primary case? Changes in the intestinal microbiotome of patients with irritable bowel syndrome (IBS) and effect of probiotics on IBS? 4. Study in 200 children Longitudinal study in contact persons of children with primary varicella infection Clinical trial administering probiotics to IBS patients and healthy volunteers PARTNERS INVOLVED STATUS
CMI analysis on vaccinees Dendritic cells as nature’s adjuvant TLR ligands as adjuvants LEH, CEV, CenStat, Artesis Ongoing
1. Analyzing CMI responses in cervical secretions 2. Development of a urine test based on HPV DNA CEV, LEH, LMM Initialized
1. Analysing humoral and cellular immunity and statistical modelling CEV, LMM, LEH, CenStat Ongoing
2. Quantitative analysis of faecal samples by phenotypic methods and population fingerprinting to elucidate/type bacterial species by denaturing gradient gel electrophoresis. 3. Quantitative analysis of faecal samples by phenotypic methods and real‐time PCR to detect differences in bacterial genera and species. 4. Questionnaires on physical activity Analyzing vaccine‐induced T cell responses by multi‐
parametric flow cytometry and in vitro restimulation cytokine assays Quantitative analysis of faecal samples by phenotypic methods and real‐time PCR to detect differences in bacterial genera and species. Leuridan et al. (BMJ, 2010, Vaccine, 2011,PIDJ 2011) Ongoing
Manuscript in preparation Ongoing
CEV, LEH, CenStat LMM, Censtat Ogunjimi et al. (Viral Immunology 2011) Ongoing Manuscript in preparation - Methusalem Report 2011 -
BASIC RESEARCH
I 1. Mechanisms of resistance and phenotypic tolerance selected by amoxicillin therapy? 1. A randomized placebo‐controlled prospective study in patients with community‐acquired lower respiratory tract infections conducted as part of the ongoing FP6 project GRACE and the ongoing FP7 project TheraEdge Manuscript in preparation 2. Mechanisms of resistance and selection dynamics of fluoroquinolones (FQs), ciprofloxacin and levofloxacin exposure on the human oropharyngeal and gastrointestinal flora? 2. A randomized placebo‐controlled trial in healthy volunteers Carriage and transmission dynamics of (resistant) bacteria? Mechanism of innate immunity in the central nervous system? Data from clinical trials in section I 1. Quantitative analysis by phenotypic methods of changes in the oral streptococcal flora and genotypic methods to study resistance mechanisms pre and post‐amoxicillin therapy. Analysing phenotypic tolerance by spectrometric quantification of elaborated β‐lactamases and visualising biofilm formation by FISH analysis. 2. Quantitation of FQ‐
resistant Escherichia coli and streptococci in faecal and throat samples pre and post‐therapy. Analysis of FQ‐resistant mechanisms and genetic relatedness of isolates by PCR/sequencing, SDS‐PAGE, growth inhibition assays, and pulsed‐field gel electrophoresis. Deterministic dynamic CEV, transmission models LMM,CenStat LEH, CenStat Manuscript in preparation 1. Best strategy to diagnose M. pneumoniae and C. pneumoniae LRTIs? 1. A prospective study in patients with community‐acquired lower respiratory tract infections LMM, CenStat Ongoing
2. Development of an evidence‐based intervention package for a more targeted antibiotic policy in lower respiratory tract infections (LRTI) in primary care in Europe, and to assess effectiveness of the implementation of this 2. Prospective case‐
control study in adults presenting with LRTI at their GP Development of multimodal imaging strategies to monitor inflammation and cellular implants/vaccines in the central nervous system. 1. Evaluation of different tests for the detection of Mycoplasma pneumoniae and C. pneumoniae in patients with lower respiratory tract infections (LRTI) 2. Development diagnostic models to differentiate between 1) viral and bacterial infections and 2) CAP and other, construct a simple algorithm that can be applied in daily practice and will enable the GP to discern patients at risk for complications from patients with self‐limiting J K L PARTNERS INVOLVED LMM, CEV, CenStat STATUS
Ongoing Ongoing 21
- Research Activities 2011 -
model disease with low risk for poor outcome Assess the quality of Time series and antimicrobial compositional analysis of consumption in longitudinal antimicrobial ambulatory care, consumption data, and hospital care and identification of nursing homes, explain appropriate outcome variation, and measure measures effect of interventions Prospective study in Differences healthy brain mice and intoxicated groups M Antmicrobial consumption and resistance patterns in Europe N Cell migration O Dendritic cells in Multiple Sclerosis 1. Predictiveness of social contacts for disease transmission P 2. Mechanisms for parvovirus B19 transmission 3. Alternative routes to estimate MMR vaccination coverage 4. Correlation between indirect costs and disease diagnosis 5. sero‐epidemiology of vaccine‐preventable infections A prospective study in MS patients 1. population survey through contact booklets registries and sero‐surveys 2. serological and immunological analysis in mother‐
infant pairs 3. immunization coverage survey analysis 4. use of available costing information in health ensurance databases 5. use of sero‐survey data BASIC RESEARCH
Evaluation of DCs and Treg in MS 1. Using serological data and social contact data to estimate infectious disease parameters 2. Estimating basic immunological processes and maternal risk for parvovirus B19 3. Estimating trivalent vaccination coverage from trivariate current status data: application for measles, mumps and rubella 4. Estimating indirect costs related to pneumococcal infections 5. Seroepidemiology of vaccine‐preventable infections. Estimating the reproduction number from final size data PARTNERS INVOLVED STATUS
LMM, CenStat JAC‐series (9 published papers) LEH, CenStat Manuscript in preparation. Ongoing LEH, CenStat CEV/CHERMID, Goeyvaerts CenStat et al. (JRSS‐C 2010) Goeyvaerts et al. (Biostatistics, 2011) Goeyvaerts et al. (Statistics in Medicine, In Press) Creemers et al. (Journal of Applied Statistics, 2011)/In progress Technical report Please note that Table 3.1 gives an overview of the joint research activities, for a detailled overview of research projects; please consult Annex VII. 22
4 DisseminationandCommunicationActivities
4.1 Scientificpapersinpeerreviewedjournals
Figure 4.1: Number of joint peer‐reviewed articles published from 2008 to 2011 Importantly, the Methusalem funding made an improved scientific collaboration with the University of Hasselt possible, which is clearly indicated by the increase in the number of joint publications, ie 4 in 2008, which increased to 21 in 2011. An overview of published peer‐reviewed papers and papers in press is given in Annex III. For an overview of all Vaxinfectio and CenStat papers, we refer to the respective annual reports and the websites (www.vaxinfectio.be and www.uhasselt.be/censtat) 4.2 MethusalemResearchDays
On March 7, 2012, the fourth joint scientific meeting of the Methusalem Consortium was held at the premises of the University of Antwerp. Two activities were organized: a workshop on linear mixed models in the early afternoon and late afternokn‐evening, a series of presentations on ongoing and future joint research collaborations within the Methusalem consortium Vaxinfectio‐CenStat, with an overview by the heads of each collaborating unit (LMM, CEV, LEH and CenStat). This fourth Research Day attracted a total of 39 participants. Within the framework of the collaboration of the University of Antwerp with France (www.ua.ac.be/Frankrijkjaar) a key note guest speaker, Prof Dr Ph. Kourilsky (Professeur au Collège de France, Membre de l’académie de Sciences) was invited to give a highly appreciated lecture entitled ‘The onset of systems immunology‘. For the programme of the Methusalem Research Day see Annex IVI. 4.3 ScientificChairinEvidenceBasedVaccinology
The need was felt among the researchers of both Vaxinfectio and CenStat to set up a more comprehensive research and education plan of action in the field of evidence based vaccinology, as part of the overall research plan of the Methusalem consortium. It was opted to establish a scientific chair, in order to make it possible to attract funding from various sources, including from private sector. The promotor of the Chair is Prof. Dr. Philippe Beutels, head of the Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID); Prof. Dr. Pierre Van Damme, head of the Centre for the Evaluation of Vaccination (CEV) and chairman of Vaxinfectio, acts as co‐
23
- Dissemination and Communication Activities -
promotor of the Chair. The Scientific Chair in Evidence Based Vaccinology (EBV) was officially established by decision of the UA Board of Directors (Bestuurscollege) on December 9, 2008. Funding for the EBV Chair has meanwhile been secured from Pfizer for four years (60.000 EUR annually). As of 1st February 2009, Prof. Dr. Niel Hens has been selected as holder of the Chair. He has been appointed as 50% Guest Professor, and combines this assignment with a position as lecturer/assistant professor at the University of Hasselt. He holds a PhD in science (mathematics) and an MSc in biostatistics and he has an excellent track record in terms of research and education. His doctoral research has been on the crossroads between the disciplines of medicine, mathematics and statistics. The EBV Chair will support research into improved estimation methods to establish the effectiveness and cost‐effectiveness of vaccination programmes, including pneumococcal conjugate vaccine programmes, as well as medical education in evidence based vaccinology. The scientific aim of this Chair is to raise the level of scientific research in the area of evidence based vaccinology, in order to match the growing scientific interests from academics and industry, and in order to achieve a high level of independent research in this area. Whereas the EBV‐Chair is not sponsored by Methusalem funding, it is the catalyst for the Methusalem collaboration between VAXINFECTIO and Censtat. 4.4 Website
To enhance the visibility and to improve dissemination activities within the Consortium, a website was recently created. The website is hosted by the University of Antwerp and can be accessed through: www.ua.ac.be/methusalem/vaxinfectio‐censtat It is available in English and contains the following parts:  Methusalem Consortium o Board of Directors o Board of Advisors  Research Objectives  Events o Annual Joint Research Days  Dissemination o Joint papers  Contact  Jobs Also links to the Vaxinfectio website (www.vaxinfectio.be) and the CenStat website (www.uhasselt.be/censtat) are made available. 24
Figure 4.2: Screenshot homepage Methusalem website 25
- Dissemination and Communication Activities -
26
5 Valorisation
5.1 RoleofIOFManagers
As from Nov 1, 2009, Dr. Vanessa Vankerckhoven started as research and innovation manager (funded by the Industrial Research Fund) at Vaxinfectio. With regard to technology transfer and intellectual property rights (IPR) efforts are made by the research and innovation manager to raise awareness among the researchers of the Consortium concerning the valorisation of research results and the possibilities concerning commercial exploitation thereof. She closely collaborates with the staff of the Interface Department on valorisation of results, licensing deals, spin‐offs possibilities and other technology transfer opportunities. She is responsible for setting‐up and maintaining collaborations with industry and attracting EU and IWT funding. She also attends courses on technology transfer organized by international organisations, such as ASTP (Assocation of Technology Transfer Professionals). Moreover, active networking during international conferences and at partnering events is important to increase visibility of the Methusalem consortium and to set‐up collaborations with academia and industry. Within Censtat, valorisation has a slightly different format given that pattents are not really applicable with respect to statistical methodology. On the other hand collaboration with industrial partners and external organizations (including several levels of Belgian/Flemisch government) has been very important for the strong growth in capacity Censtat has gone through in the last decade. For this reason Prof. Dr. Herbert Thijs received an IOF grant from Hasselt University in 2008 and therefore is responsible for the coordination of the scientific collaboration within Censtat and furthermore also within I‐Biostat. Methusalem has become one of the more important consortia within the domain of Public Health and Epidemiology for CenStat. From 2011 onwards Dr. Vanessa Vankerckhoven (IOF Vaxinfectio) and Dr. Herbert Thijs (IOF Censtat) will collaborate on a stronger and more regular basis in order to increase valorisation opportunities within Methusalem. 5.2 Collaborationwithindustry
Collaborating with industry has many advantages for the Consortium, such as clinical trial contract research, grants for research and access to specialised services. In the present research environment, collaboration with industry is unavoidable, and in some cases also a must, although we do bear in mind that this collaboration should not jeopardize the academic value and perception of the scientific work performed by the researchers. The long experience of the research groups with contracts and sponsoring from industry has led to the development of a policy to safeguard scientific independence with carefully negotiated contracts and with an emphasis on unrestricted grants and disclosure of conflicts of interest, if required. Also future collaborations will have to be clearly structured, with the required guarantees for independent scientific work. The IOF managers will closely collaborate with the Interface Services at UA and UH to ensure contracts that safeguard the scientific work and provide sufficient remuneration. Also, possibilities in terms of technology transfer will be closely monitored. 5.3 Strategic National and International Collaborations with other
researchgroups&academia
At the start of the Methusalem funding relationships with a number of other research groups in and outside the University had already been established. Since 2007, the Consortium has fostered these 27
- Valorisation -
existing relationships, but has also developed new relationships with new groups. The Methusalem Consortium has built‐up an international network and currently collaborates with over 200 scientific and industrial partners worldwide (over 50 countries). These strategic collaborations ensure access to other equipment and scientific resources not readily available at the Consortium. In addition, they create possibilities for the mobility of researchers. Both IOF managers from VAXINFECTIO and CenStat play an important role not only in fostering existing collaborating, but also in setting‐up new ones. In case new collaborations are set‐up, the IOF managers will closely collaborate with the Interface Services at UA and UH to ensure contracts that safeguard the scientific work and provide sufficient remuneration. Also, possibilities in terms of technology transfer will be closely monitored. A detailed overview of projects is available in Annex VII. 5.4 FlandersVaccine
Beginning of 2010 the set‐up of the ‘Flemish Vaccinatie Platform’, now renamed to ‘Flanders Vaccine’, was initiated by Vaxinfectio (Pierre Van Damme and Vanessa Vankerckhoven). The platform aims to bring to together expertise in the field of vaccine related research, to identify hurdles in the vaccination sector and to stimulate networking. Anno 2011, the steering committee consists of Vaxinfectio (Pierre Van Damme and Vanessa Vankerckhoven), Biomaric (Hugo Van Heuverswyn), Provaxs (Sven Arnouts) and Flandersbio (Ann Van Gysel). Relevant industrial and academic partners, including CenStat members and other Vaxinfectio scientists (LEH) are part of the platform. An inventory of available expertise in vaccine related research and device development in Flanders has been made and will allow setting‐up a database. In 2011, two large meetings were held (February and October) with an impressive participation rate from industry as well as academia active in this field. A new large meeting is planned autumn 2012. 28
6 ExternalResearchFunding
6.1 Overviewofsubmittedprojects2011
Over 40 new project proposals were submitted by the Consortium in 2011. FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT PROMOTOR OTHER FELLOW ACRONYM TITEL STATUS FWO INBEV BAILLET LATOUR FWO ASPIRANT Van Damme Pierre Siegrist Claire‐Anne not granted Beutels Philippe Hens Niel Ogunjimi Benson granted FWO ASPIRANT Van Tendeloo Viggo Willemen Yannick RHAMM as an attractive immunotherapeutic target antigen for dendritic cell‐based induction of T cell immunity to leukemia and myeloma: groundwork for the development and optimization of a clinical grade multi‐
antigenic therapeutic vaccine granted FWO ASPIRANT Berneman Zwi, Ponsaerts Peter Hoornaert Cloé In vivo identification and validation of immune‐suppressive signalling proteins and/or receptors involved in glioblastoma‐
mediated suppression of microglia FWO Goossens Herman, Onderzoeksprojecten Ieven Greet, Coenen Samuel, Loens Katherine Incidence, microbial aetiology, diagnosis and not granted prognosis of lower respiratory tract infections (LRTI) in nursing home (NH) residents and association between antimicrobial resistance and antibiotic consumption FWO Van Damme Pierre, Onderzoeksprojecten Van Tendeloo Viggo, Theeten Heidi The role of CMV‐infection in age‐related hypo‐responsiveness to influenza vaccination - External Research Funding -
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT PROMOTOR OTHER FELLOW ACRONYM TITEL STATUS FWO Beutels Philippe, Onderzoeksprojecten Hens Niel, Smits Evelien, Van Damme Pierre FWO Goossens Herman, Onderzoeksprojecten Malhotra Surbhi Quantification of varicella‐zoster virus boosting mechanisms with their public health implications for vaccination Samir Kumar‐
Singh FWO Cools Nathalie Onderzoeksprojecten
Lambert Julien, Bervoets An Characterizing host‐pathogen interactions granted and biofilm formation in patients developing pneumonia on assisted ventilation Role of dendritic cells in the development and treatment of alopecia areata: interaction with Toll‐like receptors FWO Cools Nathalie Onderzoeksprojecten
Conraads Viviane, Van Craenenbroeck Emeline The extent of bone marrow dysfunction and the potential to reverse underlying mechanisms in patients with ischemic cardiomyopathy FWO Berneman Zwi Onderzoeksprojecten
Verfaillie Catherine (KULeuven, Coordinator), Delforge Michel (KULeuven) MSC/MAPC‐based modulation of immune/inflammatory mechanisms underlying hypoplastic MDS FWO Krediet aan navorsers Cools Nathalie Immunomodulatory effects of pregnancy‐
related serum factors on autoimmune reactions in multiple sclerosis FWO Krediet aan navorsers FWO Krediet aan navorsers Smits Evelien Malhotra Surbhi In vivo non invasive imaging of immunotherapy for acute myeloid in mice Methicillin‐resistant Staphylococcus aureus: granted Exploring the 'biofilmome' for markers of infection FWO POSTDOC Berneman Zwi, Ponsaerts Peter Tambuyzer Bart Control of glioblastoma by modulation of innate immune responses in the central nervous system not granted - Methusalem Report 2011 -
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT PROMOTOR OTHER FELLOW ACRONYM TITEL STATUS FWO POSTDOC Berneman Zwi, Ponsaerts Peter Bergwerf Irene Characterization of innate immune responses in the central nervous system: modulation towards immunological acceptance of allogeneic cellular grafts not granted BOF LP Cools Nathalie, Van Tendeloo Viggo BOF ID Beutels Philippe Hens Niel, Broeckhove Jan granted IOF POC Van Damme Pierre, Vankerkhoven Vanessa Verwulgen Stijn VAX‐ID Developing and optimizing stochastic individual‐based infectious disease simulation models by parallel multicore computing techniques Bouwen van een prototype device voor de toediening van vaccins via de intradermale route IWT VIS Van Damme Pierre, Vankerckhoven Vanessa Van Gysel Ann, Sven Arnouts, Hugo Van Heuverswyn IMVIZ Immunologie, vaccinologie en infectieziekten in Vlaanderen not granted HERCULES Berneman Zwi, Ponsaerts Peter TRACER Transgenic Reporter Animal Collection for Experimental Research pending HERCULES Goossens Herman, Malhotra Surbhi Geert Mortier Next Generation Sequencing technology opening new frontiers in biological and medical research granted BiRD Pierre Van Damme, Vankerckhoven Vanessa Stijn Verwulgen, Monique Elseviers, Annouk Lievens VAX‐ID Development of a prototype device to administer vaccines by the intradermal route granted FWO NAFOSTED Van Damme Pierre, Leuridan Elke Kris Huyghe (WIV), Dang Duc Anh (Vietnam) Reducing the burden of Pertussis disease in very young infants in different epidemiological settings through pertussis vaccination in pregnancy. granted not granted - External Research Funding -
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT PROMOTOR OTHER FELLOW ACRONYM TITEL STATUS VLIR‐ZUID Van Damme Pierre, Leuridan Elke Dang Duc Anh (Vietnam) Reducing the burden of Pertussis disease in very young infants in different epidemiological settings by augmenting maternal antibody concentrations during pregnancy granted VLIR‐ZUID Goossens Herman, Malhotra Surbhi not granted EU FP7 Goossens Herman, Malhotra Surbhi Van den Wijngaart Wouter (Sweden, Coordinator) ROUTINE ROutine diagnostic tool for Urinary Tract INfections caused by Esbl and carbapenamase producing bacteria granted EU FP7 Goossens Herman, Malhotra Surbhi RGNOSIS Resistance of Gram‐Negative Organisms: Studying Intervention Strategies granted FWO coördinatieproject iTRACE granted TRACE granted IEF (Marie Curie) Goossens Herman, Greet Ieven, Katherine Loens, Samuel Coenen Goossens Herman, Greet Ieven, Katherine Loens, Samuel Coenen Beutels Philippe Bonten Marc (The Netherlands, Coordinator) Edmunds John (UK) Bilcke Joke ROTA‐DYNAMO Improving health economics of vaccines: not granted transmission‐dynamic modelling and full uncertainty analysis of rotavirus disease and vaccination ESPID‐ Training course award Van Damme Pierre‐
Leuridan Elke Summer school on vaccinology for students granted WHO‐ Training course support Van Damme Pierre‐
Leuridan Elke Summer school on vaccinology for students granted ESF - Methusalem Report 2011 -
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT PROMOTOR OTHER FELLOW ACRONYM TITEL STATUS E‐RARE Berneman Zwi GOA LOI Berneman zwi Rosenecker Joseph (Germany, Coordinator), Lutz Jean‐
Francois (France), Zegarra‐Moran Olga (Italy), Rudolph Carsten (Germany) Kumar‐Singh Samir (promotor‐
spokesperson), Giugliano Michele, Dedeurwaerdere Stafanie, Cras Patrick Evaluation of transcript replacement therapy using mRNA constructs for Cystic Fibrosis not granted Cellular and molecular characterization of central nervous system immune responses in neurodegenerative diseases and in neurostimulatory therapeutic intervention not granted Centres of Research Excellence (CRE) Scheme, National Health and Medical Research Council, Australia Beutels Philippe Professor Raina Peter MacIntyre Immunisation in under studied and special risk populations: closing the gap in knowledge through a multidisciplinary approach granted Linkage project, Australian Research Council Beutels Philippe James Wood, Tony Newall, Peter McIntyre, Robert Menzies Post‐implementation economic evaluation of childhood vaccination program second round, awaiting final decision KP BOF Pieter Moons Development of an in vitro catheter biofilm model system to evaluate the role of hospital administered fluids in facilitating initial bacterial attachment and subsequent biofilm formation. not granted - External Research Funding -
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT PROMOTOR OTHER FELLOW ACRONYM TITEL STATUS IUAP phase VII Berneman Zwi, Van Tendeloo Viggo HIV‐STOP IWT SB specialisatiebeurs Berneman Zwi, Cools Nathalie Wai Ping Lee Human immunodeficiency virus (HIV)‐1 not granted infection: research towards a functional cure Tolerogenic dendritic cells: preclinical granted development of a “negative” cellular vaccine for the treatment of autoimmunity IWT SB specialisatiebeurs Berneman Zwi Pierre Van Damme Bert Op't Eijnde (Uhasselt) Nathalie Deckx Effect of patient‐related factors on cellular mediators in multiple sclerosis not granted Johnson & Johnson Pharma Nathalie Cools Paul Cos (LMPH), Louis Maes (LMPH) Development of a fast off‐line method for the detection of microorganisms in rinsing water by means of flow cytometry granted - Methusalem Report 2011 -
6.2 Overviewofgrantedprojects2007‐2011
Figure 6.1 Number of projects Methusalem 2007‐2011 split by type of funding Figure 6.2 Obtained budget (M€) Methusalem 2007‐2011 split by type of funding For an overview of all projects and budget obtained by Vaxinfectio and CenStat respectively, we refer to the individual annual reports. Please note that the information presented for Vaxinfectio in Figures 6.1 and 6.2 was provided by ADOC (Dept of Research at UA), Vaxinfectio cannot be held responsible for possible errors. 35
- External Research Funding -
6.3 Projectproposalsinthepipeline2012
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT PROMOTOR ‐OTHER FELLOW ACRONYM TITEL DEADLINE SUBMISSION / STATUS Preklinische ontwikkeling van een geoptimaliseerd dendritische cel‐gebaseerd vaccin tegen acute myeloïde leukemie. granted Accurri Research Grant Cools Nathalie, Smits Evelien not granted BiRD Verwulgen Stijn, Bea Cantillon, Monique Elseviers Charcot Van Damme Pierre, Vorsters Alex, Vankerckhoven Vanessa Surbhi Malhotra, Herman Goossens, Julia Sabirova Smits Evelien, Ogunjimi Benson Nathalie Cools Development of a flow cytometric bead‐based assay for the detection of tumor antigen in the urine of cancer patients Urineselfsampling test Endeavour Research Fellowship Anguille Sébastien ESPID‐ Training course award Aanmoedigingsbeurs Anguille voor jonge vorsers 2011 Sébastien ‐ legaat Rosa Blanckaert BOF Doctoraatsproject BOF Klein Project 2Π 31/05/2012 Mechanistic insights on colistin resistance in granted pathogenic Escherichia coli and Klebsiella species Bert Op't Eijnde (Uhasselt) Loading human blood dendritic cells (DCs) with tumor antigen‐encoding RNA: towards the development of a more effective DC vaccine against cancer. granted Van Damme Pierre‐Leuridan Elke Summer school on vaccinology for students granted Evaluating the effect of sampling site and granted cryopreservation on blood cell counts for various subpopulations The impact of physical training on not granted cardiorespiratory fitness, muscle strength and the immunological status of patients with multiple sclerosis: dendritic cells as key modulators - Methusalem Report 2011 -
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT PROMOTOR ‐OTHER FELLOW ACRONYM TITEL DEADLINE SUBMISSION / STATUS European Commission Liason Office to Kosovo Herman Goossens Capacity building to implement state of the art surveillance systems for antibiotic consumption and resistance in Kosovo 3rd round pending FWO Krediet aan Navorsers Lion Eva pending FWO Krediet aan Navorsers Smits Evelien Enhancing tumor cell susceptibility towards natural killer cell and dendritic cell‐mediated activity. In vivo non invasive imaging of immunotherapy for acute myeloid leukemia in mice FWO onderzoeksproject Van Tendeloo Viggo, Smits Evelien FWO onderzoeksproject Van Tendeloo Viggo The added value of natural killer cells in dendritic pending cell‐based immunotherapy of cancer An Bervoets Van Ranst Marc, Keyaerts Els Role of dendritic cells in the development and pending treatment of alopecia areata: interaction with Toll‐like receptors Longitudinal quantification of viral load and pending correlates of immunity for varicella‐zoster virus and herpes simplex virus 1 in healthy individuals and patients T cell immunogenicity of RHAMM and BMI‐1: granted towards a multi‐antigen dendritic cell vaccine for hematological malignancies FWO onderzoeksproject Beutels Philippe, Van Damme Pierre, Smits Evelien Niel Hens Quantification of varicella‐zoster virus boosting granted mechanisms with their public health implications for vaccination FWO onderzoeksproject Berneman Zwi, Nathalie Cools Patrick Cras, Niels Hellings (Uhasselt), Piet Stinissen (Uhasselt), Annemie Schuerwegh (LUMC, Nederland) Innate cellular networks in multiple sclerosis pending (MS): focus on dendritic cells and on the crosstalk with mast cells FWO onderzoeksproject Beutels Philippe, Van Damme Pierre, Smits Evelien FWO onderzoeksproject Berneman Zwi, Smits Evelien, Van Tendeloo Viggo granted - External Research Funding -
FUNDING SOURCE PROMOTOR VAXINFECTIO FWO onderzoeksproject Nathalie Cools FWO Onderzoeksproject Herman Goossens, Surbhi Malhotra FWO Onderzoeksproject Beutels Philippe PROMOTOR CENSTAT PROMOTOR ‐OTHER FELLOW ACRONYM TITEL DEADLINE SUBMISSION / STATUS Luc De Clerck, Didier Ebo, Annemie Schuerwegh Identification of cellular biomarkers to predict therapy response in rheumatoid arthritis (RA) patients receiving biologicals pending The genetic basis of mechanisms of colistin resistance in Escherichia coli and Klebsiella species pending Timothy Walsh (Cardiff University) Niel Hens FWO postdoctoraal navorser Beutels Philippe Bilcke Joke FWO postdoctoraal navorser Berneman Zwi, Van Tendeloo Viggo Berneman Zwi Lion Eva Nathalie Cools FWO postdoctoraal navorser Van Damme Pierre Theeten Heidi CMV FWO project Ponsaerts Peter De Vleesschouwer Steven (KULeuven) FWO project Ponsaerts Peter, Berneman Zwi Adriaensen Dirk FWO postdoctoraal navorser Integration and representation of uncertainty in pending health economic evaluation based on dynamic transmission models: development of framework and application to influenza vaccination Improving (cost‐) effectiveness analyses of rotavirus vaccination programmes: combining dynamic modelling with in‐depth uncertainty analysis. Enhancing tumor cell susceptibility towards natural killer cell and dendritic cell‐mediated activity. The effect of cellular mediators on the modulation of innate pathogenic responses in multiple sclerosis (MS) Granted the role CMV infection in immunosenescence processes and the impact on influenza vaccine response Combined situmation of innate and adoptive immunity for eradication of central nervous system cancer neural stem cells pending Modulation of the fractalkine/CX3CR1 signalling axis in multiple sclerosis via targeted delivery of the F1 CX3CR1 antagonist. 1/04/2012 pending Granted 1/04/2012 - Methusalem Report 2011 -
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT PROMOTOR ‐OTHER FELLOW ACRONYM TITEL DEADLINE SUBMISSION / STATUS GOA Berneman Zwi Chris Vrints, Benedicte De Winter, Dorien Schrijvers, Didier Ebo Role of dendritic cells in Th1/Th17‐mediated immune diseases pending Hoge Gezondheidsraad Heidi Theeten assessment of vaccination programs granted IMI Herman Goossens Combatting antimicrobial resistance ‐ NewDrugs4BadBugs ‐ Topic 1A ‐ Combatting antimicrobial resistance 9/07/2012 IMI Herman Goossens NDBB Combatting antimicrobial resistance ‐ NewDrugs4BadBugs ‐ Topic 1B ‐ Conduct of clinical trial supporting the development of GSK 1322322 9/07/2012 Summer school on vaccinology for students granted Preclinical development of a leukemic stem cell‐
specific dendritic cell vaccine targeting BMI1 not granted Van Damme Pierre‐Leuridan Elke ISEH Eugene Goldwasser Fellowship Berneman Zwi Anguille Sébastien IWT‐SBO Berneman Zwi, Ponsaerts Peter Interuniversitaire samenwerking in het kader van de subsidie omkadering jonge onderzoekers NDBB Verfaillie Catherine (KULeuven, Coordinator) Van der Linden Annemie (EGAMI), Veerle Baekeland (KULeuven), Adrian Liston (VIB), Uwe Himmelreich (KULeuven), Alberto Pascual (Spain) INTERBRAIN Interaction‐Transcriptome‐Based Identification of not granted Small Molecules/Proteins That Affect Endogenous Neural Stem Cells, Angiogenesis And Immunomodulation In Diseased Brain - External Research Funding -
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR CENSTAT IWT‐TBM Berneman Zwi, Van Tendeloo Viggo, Smits Evelien, Vermeulen Katrien Les amis des instituts pasteur a Bruxelles Theeten Heidi MRC South Africa Herman Goossens National Cancer Plan initiative 29 PROMOTOR ‐OTHER FELLOW ACRONYM TITEL DEADLINE SUBMISSION / STATUS WT1 mRNA‐electroporated autologous dendritic cell vaccination in patients with acute myeloid leukemia at risk of relapse not granted Assessment of vaccination programs not granted Berneman Zwi, Smits Evelien, Van de Velde Ann, Anguille Sébastien NHLS Research Trust Herman Goossens Antibiotic resistant pathogenic bacteria present granted in the environment and human commensal flora: is there a link with disease? Onderzoeksmandaat Fac. GGW Berneman Zwi, Pierre Van Damme Pierre Van Damme Bert Op't Eijnde (Uhasselt) Nathalie Deckx Effect of patient‐related factors on cellular mediators in multiple sclerosis not granted Tessa Braekman Neonatal rotavirus Immunization and impact of rotavirus vaccination programmes in Belgium granted Assessment of vaccination programs not granted Vaccinatiegraad risicogroepen ad hoc project not granted Onderzoeksmandaat Fac GGW Prijs Broeckaert Depreeuw Theeten Heidi Steunpunt Welzijn Theeten Heidi Karel Hoppenbrouwers (KuLeuven) Antibiotic resistant pathogenic bacteria present pending in the environment and human commensal flora: is there a link with disease? Wilms' tumor (WT1) antigen‐targeted dendritic granted cell vaccination to prevent relapse in patients older than 65 years with acute myeloid leukemia: a multicenter randomized phase II trial (KPC_29_017) - Methusalem Report 2011 -
FUNDING SOURCE PROMOTOR VAXINFECTIO PROMOTOR ‐OTHER FELLOW ACRONYM TITEL DEADLINE SUBMISSION / STATUS Stichting tegen Kanker ‐ Berneman Zwi, asbestos clinical grants Smits Evelien, 2012 Anguille Sébastien Germonpré Paul First‐line chemoimmunotherapy using Wilms’ tumor protein 1 (WT1)‐targeted dendritic cell vaccinations for resectable malignant pleural mesothelioma pending Stichting tegen Kanker ‐ Berneman Zwi, Clinical Cancer Research Smits Evelien Stichting tegen Kanker ‐ Berneman Zwi Clinical Cancer Research Peeters Marc, Van Laethem Jean‐Luc, Hendlisz Alain Stichting tegen Kanker‐
Fundamental Cancer Research Van Tendeloo Viggo, Smits Evelien Wilms’ tumor (WT1) antigen‐targeted dendritic pending cell vaccination to prevent relapse in patients older than 65 years with acute myeloid leukemia: a multicenter randomized phase II trial. Adjuvant autologous WT1 mRNA‐loaded pending dendritic cell vaccination in combination with gemcitabine versus gemcitabine only after macroscopic complete resection of pancreatic cancer Reciprocal cross‐talk between human natural pending killer cells and interleukin‐15‐cultured dendritic cells for improved anti‐leukemic cytotoxic activity
Stichting VOCATIO Berneman Zwi De ontwikkeling van een vaccin tegen leukemie granted UA Ponsaerts Peter Anguille Sébastien TRACER Transgenic Animal Collection for Experimental Research granted Bosmans Johan, De Graeve Diana Van Gestel Raf Disentangling contributing factors for Efficient Not granted Health Production: A multilevel approach applied to cardiovascular disease interventions and hip protheses. Summer school on vaccinology for students granted UA onderzoeksmandaat Beutels Philippe PROMOTOR CENSTAT UA reisbeurs gastdocent Van Damme Pierre‐Leuridan Elke gast professor: Bonanni Paolo UA: Onderzoeksverblijf buitenland (subsidie jonge onderzoekers) Leuridan Elke Vlaams Agentschap Zorg Theeten Heidi en Gezondheid Karel Hoppenbrouwers (KuLeuven) Maternal Immunization: Challenges and Opportunities: 24‐26 septmber 2012 granted vaccinatiegraadstudie Vlaanderen 2012 granted - External Research Funding -
FUNDING SOURCE PROMOTOR VAXINFECTIO Vlir‐UOS PROMOTOR ‐OTHER FELLOW ACRONYM Van Damme Pierre‐Leuridan Elke VLK Emmanuel Van der Schueren Berneman Zwi Anguille Sébastien KOI (Korte Summer school on vaccinology for students 7/05/2012 Opleidings Initiatieven) 2013 Ontwikkeling van innovatieve methoden ter pending verhoging van de immuunstimulerende werking van dendritische celtherapie voor acute myeloïde leukemie. VLK Research Project Berneman Zwi, Van Tendeloo Viggo, Smits Evelien, Vermeulen Katrien Quantification of Wilms tumor gene (WT1) granted transcripts and immune activation to monitor the therapeutic efficacy of dendritic cell vaccination in acute myeloid leukemia WHO‐ Training course support Van Damme Pierre‐Leuridan Elke Summer school on vaccinology for students PROMOTOR CENSTAT TITEL DEADLINE SUBMISSION / STATUS granted - Methusalem Report 2011 -
6.4 Difficultiesencounteredwithobtainingadditionalfunding
The leading researchers of the Consortium at UA have encountered problems with applying for internal BOF funding, including GOA, NOI, and BOF kleine projecten, as these projects, according to internal UA regulation, do not allow submission by a promotor who already has been granted Methusalem Funding or is promotor of a Center of Excellence. This policy is however only pursued by the University of Antwerp, whereas this is not the case for other universities, including the partner University within this Methusalem Consortium, Hasselt University. This UA policy contradicts Article 14 undies of the Flemish Government Directive, which states that ‘Methusalem Funding does not exclude researchers from applying for additional funding, in particular funding from sources mentioned under Article 1bis’. It should be noted that Article 1bis refers to BOF resources (see Annex IV). Next to BOF funding, the Consortium forsees problems with future FP7, DG Sanco and other EU grant applications. Too few permanent staff is currently employed within the consortium thereby jeopardizing future grant applications for FP7, which require an input of permanent staff next to staff employed by the project. The University of Antwerp decided to limit the percentages of permanent staff to be employed for FP7 projects to 20% for ZAP (in case of coordination otherwise 10%), 5% for AAP and ATP. Next to FP7, DG Sanco and other EU grants require the input of co‐funding of 10% up to 60% which is to be financed through the input of once again permanent staff. The University decided to limit the percentages of permanent staff to be employed for these projects to 20% for ZAP (in case of coordination otherwise 10%), and to merely 5% for AAP and ATP. These rules combined with the shortage of permanent employed within the consortium makes future applications virtually impossible based on the current track record of EU projects submitted or in the pipeline as well as ongoing (see 7.1 and 7.2). 43
- External Research Funding -
44
7 HumanResources
7.1 OverviewofMethusalemPersonnel
The scientific expertise and excellence of the Consortium, grouping more than 140 staff members, is entrenched in four core research units (Laboratory of Medical Microbiology, Centre for the Evaluation of Vaccination, Laboratory of Experimental Hematology, Center for Statistics) and their leading researchers, Prof. Dr. Herman Goossens, Prof. Dr. Surbhi Malhotra (Laboratory of Medical Microbiology, LMM), Prof Dr. Pierre Van Damme (Centre for the Evaluation of Vaccination, CEV), Prof. Dr. Philippe Beutels (Centre for health economics and Modelling & Infectious Disease Modelling), Prof. Dr. Zwi Berneman and Prof. Dr. Peter Ponsaerts (Laboratory of Experimental Hematology, LEH), Prof. Dr. Viggo Van Tendeloo (Centre for Cell Therapy en Regenerative Medicine, CCRM), Prof. Dr. Geert Molenberghs, Prof. Dr. Marc Aerts and Prof. Dr. Niel Hens (Center for Statistics, CenStat). Currently, 134 staff members are employed within the Methusalem Consortium of which 85 at UA and 50 at UH (Niel Hens has a double affiliation). The distribution by personnel category from 2007‐
2010 of the Methusalem Consortium is presented in Figure 7.1. Figure 7.1 Personnel by category 2007 (n=90) – 2011 (n=134) Annex VI provides a list of staff members currently employed within the Methusalem Consortium. The Consortium applies, to the maximum extent possible, the university’s policy for equal opportunities; hence gender equality principles are being applied in the personnel policy of the Consortium. In 2007, almost 60% (53 out of 90) of the staff was female of which almost 75% (39 out of 53) belonged to the academic personnel (1 ZAP, 5 postdocs and 33 predocs). The number of women employed within the Consortium slightly decreased in 2009 to 55% (67 out of 121) of which 67% (45 out of 67) belonged to the academic personnel, but there were more women in higher positions (2 ZAP, 11 postdocs and 32 predocs). In 2010, the number slightly increased again to 57% 45
- Human Resources -
(80 out of 141) of which 71% belonged to the academic personnel (57 out of 80). Again, more women were noted in higher positions (2 ZAP, 14 postdocs, 36 predoc and 5 scientific personnel). In 2011, the number of women employed stayed quite stabile at 56% (75 out of 134) of which 73% (55 out of 75) belonged to the academic personnel. Also, women were noted in higher positions (3 ZAP, 15 postdocs and 33 predocs). 7.2 OpportunitiesforPostdoctoralResearchers
Due to its relative size, the Consortium tries to offer career opportunities and perspectives for young researchers, as well as a career perspective to more established researchers. From 2007 to now, four postdocs were promoted to ZAP(BOF) of which three in 2011 and several PhD students were offered a postdoc position. The Methusalem Consortium was also in, terms of gender equality, able to offer career perspectives for women. From 2007 to now, two postdocs were promoted to ZAP(BOF) and 9 PhD students were offered a postdoc position. Also, since 2009 Vaxinfectio has a young female postdoc appointed as IOF (Industrial Research Fund) manager (now called research & innovation manager) for Vaxinfectio. This position is being paid by the Industrial Research Fund (IOF) of the University of Antwerp. The Consortium is investing in proper and suitable training and guidance for their young predoctoral researchers under the spupervision of its postdoctoral researchers. Also, the Methusalem Consortium has adopted the policy that specific training and education needs will be identified and incorporated as much as possible for each individual staff member. Nevertheless, additional funding and career perspectives are needed to enable sufficient long‐term perspectives for postdoctoral staff. 7.3 PhDstudents&PhDsobtained
In 2007, a total of 43 PhD students were employed within the Consortium. This number further increased to 61 in 2011. Figure 8.2 gives an overview of the PhD students in 2007 to 2011. Figure 8.3 clearly shows that the vast majority of all newly recruited PhD students are being paid through external funding. Moreover, more than 80% of the PhD students are being paid by external funded projects (national and international funding). The percentage of PhD students funded by UA/UH decreased in 2011. Figure 7.2 PhD Students 2007‐2011 46
Figure 7.3 External vs UA/UH funding of PhD students To date, 36 PhDs have been succesfully obtained within the Consortium (since 2007): Date defense
Name First Name PromotorA PromotorB CopromotorA CopromotorB BERGWERF Irene Berneman Ponsaerts 2010
BEUNCKENS Caroline Molenberghs 2007
BILCKE Joke Beutels Van Damme Aerts M 2011
BOLLAERST Kaat Aerts 2009
COOLS Nathalie Berneman 2007
CREEMERS An Aerts Hens 2011
DE VOS Beatrice Van Damme Van Ranst M 2011
GADDAH Auguste Braekers 2010
GOEYVAERTS Nele Hens Aerts Beutels 2011
HALDERMANS Philippe Shkedy 2010
JACOBS Tom Molenberghs 2009
KADANKOVA Tetyana Veraverbeke 2009
KASIM Adetayo Shkedy 2010
LAENEN Annouschka Molenberghs 2008
LIN DAN Shkedy 2008
LITIERE Saskia Molenberghs 2007
LOENS Katherine Goossens Ieven 2007
MARINGWA John Geys/Faes 2008
MASSONET Goele Janssen 2008
MEBIS Jeroen Berneman Goossens 2010
NAMATA Harriet Aerts 2008
NKOUIBERT Pryseley Assam 2009
PRAMANA Setia Shkedy Lin 2011
REEKMANS Kristien Berneman Ponsaerts 2011
SERROYEN Jan 2007
SMITS Evelien Berneman Van Tendeloo Ponsaerts 2008
SOTTO Cristina Molenberghs 2009
THEETEN Heidi Van Damme Beutels Hoppenbrouwers 2011
TILAHUN Abel Molenberghs 2009
47
- Human Resources -
VAEL Karel Goossens 2011
VALKENBORG Dirk Burzykowski 2008
VAN DRIESSCHE Ann Berneman Van Tendeloo 2011
VAN SANDEN Suzy Burzykowski 2008
VANKERCKHOVEN Vanessa Goossens Wiertz Huys 2009
WOUTERS Kristien Molenberghs 2008
ZHU Qi (Aileen) Burzykowski 2010
The Methusalem Consortium will persue the policy to obtain a double diploma for PhDs in which a substantial collaboration with CenStat led to the work described in the PhD thesis. We expect that 23 PhDs will be obtained during the next 2 years (2012‐2013): Name 48
Foreseen defense date ADRIAENSSENS Niels 2012 DEL FAVA Emanuele 2012 LEURIDAN Elke 2012 MICHIELS Barbara 2012 MINALU AYELE Girma 2012 PRAET Jelle 2012 SABBE Martine 2012 TESHOME AYELE Birhanu 2012 VAN HEIRSTRAETEN Liesbet 2012 ZAKARIA Nadia 2012 ANGUILLE Sebastien 2013 CASTRO SANCHEZ Amapro (Yovanna) 2013 CLAESEN Jürgen 2013 DE VOCHT Nathalie 2013 GROUWELS Yves 2013 HABTEAB GHEBRETINSAE Aklilu 2013 HUTSE Veronik 2013 KHAMIAKOVA Tatsiana 2013 MILANZI Elasma 2013 NJERU NJAGI Edmund 2013 NUYTS Amber 2013 VERSPORTEN Ann 2013 VORSTERS Alex 2013 ZARB Peter 2013 - Methusalem Report 2011 -
8 Budget&Investments
8.1 Overallbudget2008‐2014
3.453.079 EUR (incl.10% overhead) for the University of Antwerp part, and 1.726.540 EUR (incl. 10% overhead) for the Hasselt University part. Thus, for the period 2008‐2014, the total Methusalem budget amounts to 5.179.619 EUR. 8.2 BudgetVaxinfectio
The resources of the Methusalem programme are considered as a continuous basic investment fund in support of ongoing and future research. Next to Methusalem Funding, the Consortium has also applied for additional external and internal funding (see heading 5: External Research Funding) and will continue to apply for resources in terms of projects and scholarships from traditional research funding agencies such as BOF, FWO, IWT, EU and others, to complement or increase the Methusalem funding. A central operational budget has been set aside to strengthen the collaboration among the participating research teams, and to develop new common collaborations with other teams in and outside the consortium and the 2 universities. The remaining budget at UA has been divided equally among the three leading research groups, as to provide them with a minimum of means to implement their research activities. Investmentsinexpertpersonnel2011
CEV has continued the funding of expert personnel for vaccine study coordination and improvement of internal quality of vaccine studies (e.g. drafting SOPs) as well as for translational research in collaboration with the industry. This investment has led to a diversification of the number of companies that have initiated vaccine trials at the clinical trials centre. Meanwhile, the investment in this expert personnel has led to an increased capacity for research project and protocol development. LMM has recruited one post‐doc researcher to work on the newly granted RAPP‐ID project (EU‐IMI) as a project manager as well as on the ongoing biofilm projects. All PhD students are working on a PhD thesis of which the topics are in line with the newly granted EU and non‐EU projects. Moreover, several new EU‐funded and non‐EU funded projects have started or will start as from 2012 for which additional personnel (PhD students as well as postdoc researchers) will be recruited. One post‐doc researcher has been paid from the Methusalem budget in 2011. She obtained a ZAPBOF position in October 2011. LEH continues the funding of expert personnel for the analysis of cellular immunity in longitudinal vaccine trials performed by CEV as well as for fundamental and translational immunology research related to cancer, autoimmune diseases and neurotraumas. In October 2011, LEH has recruited 1 additional lab technician involved in the preparation of therapeutic DC vaccines to treat cancer patients. Also in October, two new PhD students started in order to investigate immune‐modulatory effects of patient‐related factors as well as new treatment modalities in multiple sclerosis. Additionally, two new PhD‐students started in 2012 on the topics of microglial cell behaviour and modulation in multiple sclerosis and glioblastoma. In collaboration with CEV, a lab technician was recently (January 2012) recruited within the framework of the IOF project to investigate correlates of cellular immunity following prophylactic HPV vaccination. Investmentsinstate‐of‐the‐arttechnologies,methodologiesandequipment2011
It is obvious that an investment in the latest available technologies and equipment is a must, if the 49
- Budget & Investments -
Consortium wishes to remain in the forefront of academic research. The investments in specific equipment have been determined by the ongoing and future research topics. The Methusalem funding made investment in specific equipment possible: EQUIPMENT at LEH 1. Microscopy facility Part of Methusalem funding was used to co‐finance the establishment and maintenance of an internal microscopy facility. The current set‐up includes: (i) a new Olympus BX51 fluorescence microscope (+ Z‐axis controller) equipped with an Olympus DP71 digital camera, and (ii) a refurbished Leica inverted fluorescence microscope with an Olympus UC30 digital camera. Additionally, Olympus deconvolution and Tissuequest fluorescence analysis software is available for respectively image enhancement and quantitative data analysis (i.e. digital image conversion to FACS‐like images for co‐
localisation studies). LEH has expanded the facilities for molecular biology with a CFX96 real time PCR system. 2. Transgenic mouse collection Part of Methusalem funding was used to co‐finance the establishment and housing of an internal transgenic mouse collection for in vivo cell transplantation and immunogenicity research. This collection includes the following transgenic mice: FVB‐Luc, FVB‐eGFP/Luc, albino C57BL/6, C57BL/6‐
eGFP and C57BL6‐CX3CR1/eGFP. All equipment is available for use by all members of the Consortium. EQUIPMENT at LMM Due to the shift of the Laboratory of Medical Microbiology to the renovated 6th floor of Building S at the University of Antwerp, Campus Drie Eiken, investments were done in new equipment for the lab, including a biosafety cabinet, an analytical balance, an ice machine and an industrial washing machine. Future Investments in state‐of‐the‐art technologies, methodologies and
equipment
The consortium will continu to invest in state‐of‐the‐art technologies, methodologies and equipment to remain in the forefront of academic research. As it is planned now by the UA infrastructure department, the move of the CEV clinical trial team to the second floor of Building S will take place in 2013. From experience with previous moves, CEV plans to make some financial provisions for extra costs that will not be covered by the central infrastructure budget. CCRG is gearing up to obtain a manufacturing authorization (MA) of investigational medicinal products (IMP’s) from the Belgian authorities (FOD‐Public Health) and will likely undergo an early‐
phase GMP inspection in 2011. Eventually, this will allow the production of IMP for multicenter clinical trials between different EU member states in the field of cancer vaccination. 8.3 BudgetCenStat
CenStat considers the Methusalem funding a continuous reseach fund. The CenStat budget is used to fund predoctoral positions focusing on statistical methodology within the collaboration with all research partners at UA. In addition, a part time postdoctoral position, overseeing the collaboration between CenStat and Vaxinfectio is funded. Next to the Methusalem funding, CenStat continuously applies for additional external and internal funding and will continue to apply for resources in terms of projects and scholarships from traditional research funding agencies such as BOF, FWO, IWT, EU, and others, to complement or increase the Methusalem funding. Furthermore, Methusalem funding 50
has been used to buy laptops and powerful desktops as well as to fund participation at scientific conferences of its Methusalem‐funded researchers. Investmentsinexpertpersonnel2008‐2011
During the period 2008‐2012 two predoctoral researchers completed their PhD while working on the Methusalem grant. During 2008‐2009, Niel Hens worked as a postdoctoral researcher on the Methusalem grant. In 2010, CenStat attracted a third predoctoral researcher focusing on modelling epidemic data in collaboration with the research partners at UA. In 2011, a new postdoctoral fellow was partly funded by the Methusalem project. FutureInvestments
In 2012 two new PhD students and one postdoctoral fellow will be hired to work on the Methusalem grant. Prof. Dr. Niel Hens who holds a shared UHasselt‐UA appointment will continue to supervise the collaboration between CenStat and Vaxinfectio. CenStat will continuously recruit new pre‐ and postdoctoral researchers to maximize the implementation of the Methusalem research plan. It will also activate participation at international conferences by presentations and short courses presenting up‐to‐date statistical methodology as used in the research activities of the consortium. 51
- Budget & Investments -
52
9 Annexes
Annex I: Administrative information Annex II: Minutes of the Board of Directors Annex III: List of joint peer‐reviewed papers Annex IV: Programme of the Methusalem Research Day Annex V: Extract from the Flemish Government Directive Annex VI: Personnel list Annex VII: List of ongoing projects 53
- Annex I -
54
ANNEXI:AdministrativeInformation
Team leader at the University of Antwerp: Prof. Dr. Herman Goossens Responsibile for the scientific and technical coordination of the project at the University of Antwerp. Address: Medical Microbiology, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐821.37.87 Fax number: +32‐3‐825.42.81 Email: [email protected] Leading researchers: They are leading the core and collaborating research units, which constitute the Centre of Excellence, Vaxinfectio. 1. Prof. Dr. Pierre Van Damme Address: CEV, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.38 Fax number: +32‐3‐265.26.40 Email: [email protected] 2. Prof. Dr. Zwi Berneman Address: Hematology, UZA, Wilrijkstraat 10, BE 2650 Edegem Telephone: +32‐3‐821.37.80 Fax number: +32‐3‐821.42.86 Email: [email protected] 3. Prof. Dr. Samuel Coenen Address: Centre for General Practice, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.25 Fax number: +32‐3‐265.25.26 Email: [email protected] 3. Prof. Dr. Philippe Beutels Address: CHERMID, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.38 Fax number: +32‐3‐265.27.52 Email: [email protected] 4. Prof. Dr. Viggo Van Tendeloo Address: CCRG, UZA, Wilrijkstraat 10, BE 2650 Edegem Telephone: +32 3 821 36 61 Fax number: +32 3 821 44 56 Email: [email protected] or [email protected] Team leader at Hasselt University: Prof. Dr. Geert Molenberghs Responsibile for the scientific and technical coordination of the project at Hasselt University. Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.38 or +32‐11‐26.82.02 Fax number: +32‐11‐26.82.99 Email: [email protected] Leading researchers: 1. Prof. Dr. Marc Aerts 55
- Annex I -
Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.47 or +32‐11‐26.82.02 Fax number: +32‐11‐26.82.99 Email: [email protected] 2. Prof. Dr. Niel Hens Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.32 or +32‐11‐26.82.02 Faxumber: +32‐11‐26.82.99 Email: [email protected] Research and Innovation Manager (IOF): Responsible for overall management and technology transfer of the Vaxinfectio & Methusalem consortium. Dr. Vanessa Vankerckhoven Address: Medical Microbiology, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.21.57 Fax number: +32‐3‐265.27.52 E‐mail: [email protected] Administrative coordinator: Responsibile for the administrative and financial coordination of the Vaxinfectio & Methusalem consortium. Gino Verwimp Address: Department of Epidemiology and Social Medicine, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.21 Fax number: +32‐3‐265.26.40 Email: [email protected] Recipient institution 1: University of Antwerp Legal address: Contact address: Stadscampus Campus Drie Eiken Prinsstraat 13 Universiteitsplein 1 BE 2000 Antwerpen BE 2610 Antwerpen Recipient institution 2: Hasselt University Legal and contact address: Campus Diepenbeek Agoralaan 1 BE 3590 Diepenbeek Participating institution: Universitair Ziekenhuis Antwerpen (UZA) Legal and contact address: Wilrijkstraat 10 2650 Edegem 56
ANNEXII:MinutesofthemeetingoftheBoardofDirectors
UA‐UH METHUSALEM CONSORTIUM VAXINFECTIO‐CENSTAT Minutes of the Board of Directors Meeting Date: Thursday 12 January 2012, 10:30 till 13:00 hrs Venue: University of Antwerp, Faculty of Medicine and Health Sciences, Campus Drie Eiken, Universiteitsplein 1, 2610 Antwerp Building S, Room 138 Chair: Prof. Herman Goossens Vice‐Chair: Prof. Geert Molenberghs Participants The Board of Directors of the UA‐UH Methusalem Consortium Vaxinfectio‐CenStat is composed of the heads of the 4 participating core research groups, the (part‐time) ZAP members (9), all postdoctoral researchers (14), the Vaxinfectio Research & Innovation ('IOF') Manager, the designated administrative coordinator, the administrative officers of the Department of Research of UA and UH, and the respective chairmen of the Research Councils UA and UH: Composition per (per 01/10/2011): Present number: 32 Goossens Herman, Chair and Head LMM (UA) Molenberghs Geert, Vice‐chair and Head CenStat (UH) Van Damme Pierre, Head CEV (UA) Berneman Zwi, Head LEH (UA) Vankerckhoven Vanessa, Research & Innovation Manager (IOF) – (UA) Verwimp Gino, Administrative coordinator (UA) Spruyt Eric , Head Department of Research, ADOC (UA) Peters Ann, Head Research Coordination (UH) Timmermans Jean‐Pierre, Chairman Research Council (UA) Janssen Paul, Chairman Research Council (UH) Aerts Marc (100% ZAP) (UH) Beutels Philippe (100% ZAPBOF) (UA) Faes Christel (100% ZAP) (UH) Hens Niel (100% ZAP) (UA/UH) Malhotra Surbhi (100% ZAPBOF) (UA) Shkedy Ziv (100% ZAP) (UH) Van Tendeloo Viggo (100% ZAPBOF) (UA) Coenen Samuel (30% ZAP) (UA) Ieven Greet (10% ZAP) (UA) Ponsaerts Peter (10% ZAP) (UA) Schroyens Wilfried (10% ZAP) (UA) Van Herck Koen (10% ZAP) (UA) Andraud Mathieu (100% postdoc BAP) (UA) Anthierens Sibyl (80% postdoc BAP) (UA) 57
- Annex II -
Cools Nathalie (100% postdoc BAP) (UA) Goeyvaerts Nele (100% postdoc BAP) (UH) Lion Eva (100% postdoc BAP) (UA) Loens Katherine (80% postdoc BAP) (UA) Moons Pieter (100% postdoc BAP) (UA) Smits Evelien (100% postdoc BAP) (UA) Theeten Heidi (100% postdoc BAP) (UA) Vermeulen Katrien (100% postdoc BAP) (UA) Present at the meeting (17): Herman Goossens Heidi Theeten Gino Verwimp Geert Molenberghs Koen Van Herck Pierre Van Damme Vanessa Vankerckhoven Peter Ponsaerts Paul Janssen (Research Office UHasselt) Pieter Moons Zwi Berneman Niel Hens Samuel Coenen Nathalie Cools Eva Lion Evelien Smits Kristien Reekmans Agenda  Welcoming (Geert Molenberghs en Herman Goossens) and short introduction of participants  Overview of the activities of the Methusalem annual report (Herman Goossens)  Feed‐back on evaluation of Methusalem report and activities (ADOC UA; Research Office UHasselt)  Strategic research plan (Geert Molenberghs, Zwi Berneman, Herman Goossens, Pierre Van Damme)  Organisation Methusalem day 4: brainstorming  General discussion  Lunch Meeting report Welcoming (Geert Molenberghs en Herman Goossens) and short introduction of participants Prof. Goossens, chair of the meeting, and Prof. Molenberghs, vice‐chair, welcome the members present at the meeting. As introduction, the members are requested to briefly present their background and present activities. He further explains that the Board of Directors is responsible for the management of the consortium, and more specifically for setting the guidelines of the scientific strategy to be developed. Overview of the activities of the Methusalem annual report (Herman Goossens) Prof. Goossens presents an overview of the track record of the consortium, referring specifically to (1) the increasing number of joint publications (28 reported), way above the output of the other UA‐UH consortia, (2) the growing number of staff of the research group (29 ATP, 65 PhD), and (3) the success ratio in attracting external funding (80% of the PhD researchers are funded with external resources). As such, the consortium has proven that it provides added value for the Methusalem budget invested in its activities. Issues that remain and that are considered as threats to further growth are (1) the incompatibilities that have been imposed in terms of access to other funding opportunities from the Special Research Fund, (2) finding sufficient co‐funding (in terms of permanent staff) for EU projects, (3) limited opportunities for young postdoctoral researchers to continue their careers, (4) and the fact that 1 IOF manager is insufficient to explore all possible opportunities for valorisation of research results, given the size of the overall consortium. 58
His conclusion is that we have consolidated in a pleasant cooperation, with an added value in terms of funding, also from industry, in terms of research opportunities and in terms of scientific output. Feed‐back on evaluation of Methusalem report and activities (ADOC UA; Research Office UHasselt) Prof Paul Janssen explains the background of the cooperation UA‐UH in 4 Methusalem network projects, being VAXINFECTIO‐CenStat, ECO, NANO and NEURO. This was an initiative of the former vice‐rector Dirk Van Dyck, to support 'top' research between the two institutions and to create economies of scale with the limited resources of the UH. A collaboration agreement was concluded between UH and UA on the Methusalem funding. According to the terms of this collaboration agreement, there should be an initiative for a joint evaluation at the end of the 4th year. This evaluation was held on 10/10/2011 in Hasselt, as a 'teasing' exercise to boost the plans for joint scientific output, and without any formal repercussions. Special attention was given to the concrete collaboration, the joint project proposals, joint output and valorisation initiatives (IOF). Prof Janssen lists the following conclusions for the VAXINFECTIO ‐CenStat consortium:  The number of joint publications (12) was considered as relatively low, given the overall output and the relative size of the consortium;  the analysis of the strengths and weaknesses is at the level of VAXINFECTIO, not at the level of the consortium;  the way the information is presented in the annual report (specifically the graphs and listings) makes it impossible to see which results are specifically attributable to the Methusalem funding.  The actual use of the Methusalem funding is also not clear. It is advised to more clearly specify for which investments in equipment, operational costs or personnel costs the Methusalem funding has been used.  Cooperation in terms of PhD development is not clearly reported.  The role of the IOF manager is not clearly expressed in the reporting. At UH, there is also an IOF manager, Herbert Thijs. It is advised that both managers should cooperate more closely as to boost the possible IOF related output (incl. IPR) within the consortium.  The evaluation report will be made available shortly. Prof. Goossens and Prof. Hens formulate the following remarks in reply:  The Methusalem funding has been considered as a 'lever' to attract other additional funding.  In terms of EU co‐funding, there is no more room because of limited permanent staff and restrictive accounting rules. Thus there is need for clearer constructions.  The 'teasing' has been understood: the VAXINFECTIO ‐CenStat consortium acts as an example for the other consortia, especially in terms of joint publications, organisation of research days, and of joint project proposals.  It is a fact that Methusalem (co‐)promotors have restricted access to other BOF funding at UA. This is not the case at UH, where there is even a structural funding for the successful research institutes.  The issue of strengthening the IOF collaboration within the Methusalem consortium is appreciated. It is explained that the IOF consortium at UA has been initiated at the same time and parallel to the Methusalem consortium. As both have a different overall objective (fundamental/basic research compared to applied/industrial research), the reporting cycle has been differentiated.  It is agreed that the listed shortcomings in the annual reports will be corrected in the next issue. In the overall conclusion, the colleagues of UH and UA expressed that they are very satisfied with the collaborative attitude on both sides, and are looking forward to continue the Methusalem cooperation even beyond the first cycle of 7 years. Strategic research plans The research activities and research opportunities are presented by resp. Geert Molenberghs for CenStat, Zwi Berneman for LEH, Herman Goossens for LMM, and Pierre Van Damme for CEV/CHERMID. The respective presentations are available from the presenters at explicit request. The added value of the VAXINFECTIO ‐CenStat Methusalem consortium can be seen in the following elements that are referred to during these presentations: ‐ direct access to a wide range of disciplines in the biomedical and statistical‐mathematical field; 59
- Annex II -
‐ more output in the respective research areas of the research groups involved; ‐ more focus on interdisciplinary and multidisciplinary research in all research groups; ‐ high quality output in fundamental research; ‐ more efficient and effective use of data; ‐ focus on wider collaborative projects. The meeting provided again an opportunity to find linkages between the different research topics and research projects, ongoing as well as planned, between the various research units within the consortium. Organisation Methusalem day 4: brainstorming The date of the Methusalem Research day has been set on 7 March, as to coincide with a presentation on molecular immunology by Prof Philippe Kourilsky, College de France, French Academy of Sciences. He has been invited by the Vice‐rector Johan Meeusen in the framework of this year's focus on the 'France Year'. In addition, he will give a second presentation on "Altruism" on 8 March. The presentation of Kourilsky will be used as a keynote lecture, and is scheduled at the end of the programme. Various ideas are put forward how to fill in the rest of the programme for the research day:  Last year's initiative to organise a specific statistical training workshop was considered as very useful, thus it is proposed to organise a new session. A consultation will be made as to check which topics will be preferred.  It is important to facilitate the contacts between predoctoral and postdoctoral researchers; therefore interactive poster sessions could be a useful instrument.  Another proposal is to organise a "meet the expert" session.  It is important that the target audience for the specific training and information activities is clearly defined: predoc? postdoc? Biomedical? Wider scientific population?  The number of topics should be kept to a minimum (max. 3) These ideas will be taken into consideration by the Board of Directors when developing the final programme of the Research Day. The research day was organised as follows: The meeting is scheduled to start at 14h00 with a workshop on 'Generalized Linear Models and Extensions in R' particularly focused but not restricted to PhD‐students, followed by the meeting of the Methusalem Consortium at 17h00, including a keynote lecture by Philippe Kourilsky (Institut Pasteur, France) on Immunology. General discussion In the general discussion, the role of Prof Niel Hens as a focal point in the VAXINFECTIO‐CenStat interactions is discussed. He is providing support to an increasing number of master students, predocs and postdocs, and it is important that he can continue this in a sustainable way. Other joint funding opportunities are briefly discussed: 'Steunpunt Welzijn', IMI, VLIR IUS with country strategies in 5 countries (Uganda, Tanzania, Cuba, Ecuador, Vietnam), VLIR VLADOC. Finally, the meeting discusses the administrative and financial management constraints associated with a multitude of funding sources, with each their own specific needs and requirements. There is clearly a need to allocate additional administrative support to research groups to allow them to cope with the additional administrative burden. The meeting is closed at 13.00hrs. with a walking lunch. ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ GV, 2/2012 60
ANNEXIII:Listofjointpeer‐reviewedPapers2011

















Adriaenssens N., Coenen S., Versporten A., Muller A., Minalu G., Faes C., Vankerckhoven V., Aerts M., Hens N., Molenberghs G and Goossens H. on behalf of the ESAC Project Group.European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997–2009). In: J Antimicrob Chemother 2011; 66 Suppl 6: vi3–vi12 Adriaenssens N., Coenen S., Versporten A.,Muller A., Minalu G.,Faes C., Vankerckhoven V.,Aerts M., Hens N., Molenberghs G. and Goossens H on behalf of the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997–2009). In: J Antimicrob Chemother 2011; 66 Suppl 6: vi47–vi56 Adriaenssens N., Coenen S., Versporten A., Muller A., Minalu G., Faes C.,Vankerckhoven V., Aerts M., Hens N., Molenberghs G. and Goossens H. on behalf of the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe (1997–2009). In: J Antimicrob Chemother 2011; 66 Suppl 6: vi37–vi45. Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N & Beutels P (2011) Estimating the age‐specific duration of herpes zoster vaccine protection: a matter of model choice? IN: Vaccine, DOI: http://dx.doi.org/10.1016/j.vaccine.2011.09.079. Coenen S., Adriaenssens N., Versporten A.,Muller A., Minalu G., Faes C., Vankerckhoven V., Aerts M., Hens N., Molenberghs G.and Goossens H. on behalf of the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): outpatient use of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in Europe (1997–2009). In: J Antimicrob Chemother 2011; 66 Suppl 6: vi57–vi70. Creemers, A., Aerts, M., Hens, N., Shkedy, Z., Desmet, F. and Beutels, P. Revealing agespecic past and future unrelated costs of pneumococcal infections by exible generalized estimation equations. In: Journal of Applied Statistics. Volume 38 Issue 8, 1533. Faes C., Molenberghs G., Hens N., Muller A.,Goossens H. and Coenen S. Analysing the composition of outpatient antibiotic use: a tutorial on compositional data analysis. In: J Antimicrob Chemother 2011; 66 Suppl 6: vi89–vi94. Goeyvaerts, N., Hens, N., Aerts, M. and Beutels, P. Model structure analysis to estimate basic immunological processes and maternal risk for parvovirus B19. In: Biostatistics, 12, 283‐302. Goeyvaerts, N., Hens, N., Theeten, H., Aerts, M., Van Damme, P. and Beutels, P. Estimating vaccination coverage for the trivalent measles‐mumps‐rubella vaccine from trivariate serological data. In: Statistics in Medicine, In press. Hens N., Van Ranst M., Aertsa M., Robesynd E,Van Damme P., Beutels P. Estimating the effective reproduction number for pandemic influenza from notification data made publicly available in real time: A multi‐countryanalysis for influenza A/H1N1v 2009. In: Vaccine 29 (2011) 896–904. Lefevere E., Hens N., Theeten H., Van den Bosch K., Beutels P., De Smet F.,Van Dammed P. Like mother, like daughter? Mother’s history of cervical cancer screening and daughter’s Human Papillomavirus vaccineuptake in Flanders (Belgium). In: Vaccine 29 (2011) 8390– 8396. Lefevere E., Hens N. De Smet F., Van Damme P. Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007‐2009: a Cox regression model. In: BMC Public Health 11, 4700 (2011) Leuridan E, Hens N, Hutse V, Aerts M, Van Damme P. (2011) Kinetics of maternal antibodies against rubella and varicella in infants. Vaccine Mar 3;29(11):2222‐6. Leuridan E., Hens N., Peeters N., de Witte L., Van der Meeren O., Van Damme P Effect of a Prepregnancy Pertussis Booster Dose on Maternal Antibody Titers in Young Infants In: The Pediatric Infectious Disease Journal Volume 30, Number 7, July 2011 Leuridan E., Hens N., Peeters N., De Witte L., Van Damme P. Effect of an Adult Pertussis Booster Dose on Maternal Antibody Titers in Young Infants. In: PIDJ. In Press. Luyten, J., Marais C., Hens, N., De Schrijver, K. and Beutels, P. Imputing QALYs from single time point health state descriptions on the EQ‐5D and the SF‐6D: a comparison of methods for hepatitis A patients. In: Value in Health. In Press. Minalu G., Aerts M., Coenen S., Versporten A., Muller A.,Adriaenssens N., Beutels P., Molenberghs G., Goossens H.and Hens N. Application of mixed‐effects models to study the country‐specific outpatient antibiotic use in Europe: a tutorial on longitudinal data analysis. In: J Antimicrob Chemother 2011; 66 Suppl 6: vi79–vi87 61
- Annex III -



62
Ogunjimi, B., Smits, E., Hens, N., Hens, A., Lenders, K., Ieven, M., Van Tendeloo, V., Van Damme, P., Beutels, P. Exploring the impact of exposure to primary varicella in children on varicella‐zoster virus immunity ofparents. In: Viral Immunol. 2011 Apr;24(2):151‐7. Versporten A.,Coenen S., Adriaenssens N.,Muller A., Minalu G., Faes C.,Vankerckhoven V., Aerts M., Hens N.,Molenberghs G. and Goossens H. on behalf of the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe (1997–2009). In: J Antimicrob Chemother 2011; 66 Suppl 6: vi25–vi35 Versporten A., Coenen S., Adriaenssens N.,Muller A.,Minalu G.,Faes C, Vankerckhoven V., Aerts M., Hens N.,Molenberghs G. and Goossens H. on behalf of the ESAC Project Group. European SurveillanceofAntimicrobial Consumption (ESAC): outpatient penicillin use in Europe (1997–2009). In: J Antimicrob Chemother 2011; 66 Suppl 6: vi13–vi23 - Methusalem Report 2011 -
63
- Annex IV -
19.55 – 20.00 Concluding remarks Herman Goossens, UA 20.00 Reception @ De Foyer 64
ANNEXV:ExtractsoftheFlemishGovernmentDirective
HOOFDSTUK [Ibis.] - Financieringsbeginselen
B.Vl.R. 24-1-2003
Artikel [1bis.]
§ 1 Elk van de universiteiten, bedoeld in artikel 3 van het decreet van 12 juni 1991
betreffende de universiteiten in de Vlaamse Gemeenschap, brengt de financiële middelen die
door de Vlaamse Gemeenschap overeenkomstig artikel 168 van het decreet worden
bijgedragen voor wetenschappelijk onderzoek, onder in een intern bestemmingsfonds,
genoemd "Bijzonder Onderzoeksfonds".
§ 2 Onder de term "de middelen van het Bijzonder Onderzoeksfonds" wordt in dit Besluit
verstaan : de overheidsbijdragen bedoeld in artikel 2 van dit besluit, aangevuld met de eigen
bijdrage, bedoeld in § 1 van artikel 6 van dit besluit.
§ 3 Ieder jaar voor 1 oktober deelt de Vlaamse regering aan elke universiteit het bedrag mede
van de overheidsbijdragen die zij krachtens artikel 2 van dit besluit kunnen verwachten. De
raming van de inkomsten en de uitgaven van het Bijzonder Onderzoeksfonds maakt integraal
deel uit van de begroting van de universiteit onder de afdeling IV.
§ 4 De overheidsbijdragen aan het Bijzonder Onderzoeksfonds worden door de Vlaamse
Regering definitief vastgesteld van zodra de algemene uitgavenbegroting van de Vlaamse
Gemeenschap voor het desbetreffende begrotingsjaar is vastgelegd.
[Hoofdstuk IVbis. - De Methusalem-financiering voor internationaal toonaangevende
onderzoekers
Afdeling 1. - Algemeen
Art. 14bis.
Voor het toekennen van langetermijnprogramma-financiering aan een beperkt aantal
uitmuntende ZAP-leden, verbonden aan universiteiten in de Vlaamse Gemeenschap, wordt
per universiteit een overheidsbijdrage, verder de Methusalem-financiering genoemd,
toegekend.
De Methusalem-financiering wordt toegekend en aangewend overeenkomstig de voorwaarden
gesteld in dit hoofdstuk.
Afdeling 2. - Kenmerken van de financiering
Art. 14ter.
§ 1. Voor het begrotingsjaar 2006 wordt de Methusalem-financiering vastgesteld op
3.000.000 euro. Dit bedrag geldt als referentiebedrag. Binnen de perken van de
65
- Annex V -
begrotingskredieten wordt de subsidie geleidelijk verhoogd in de periode 2007-2010 om in
2010 haar hoogtepunt te bereiken.
§ 2. De Methusalem-financiering wordt jaarlijks geïndexeerd, conform artikel 2, § 2.
§ 3. De verdeling van de Methusalem-financiering over de Vlaamse universiteiten gebeurt
overeenkomstig de in artikel 3 bedoelde verdeelsleutel.
§ 4. De Methusalem-financiering wordt met behoud van bestemming toegevoegd aan het
Bijzonder Onderzoeksfonds.
De aan het Bijzonder Onderzoeksfonds toekomende middelen die na afloop van het betrokken
kalenderjaar niet zijn toegewezen, kunnen met behoud van bestemming worden overgedragen
naar de begroting van de universiteit.
§ 5. Het staat de universiteiten vrij het beschikbare bedrag voor de Methusalem-financiering
te verhogen :
1° uit eigen middelen en/of
2° uit het onbestemde deel van het Bijzonder Onderzoeksfonds.
De in het eerste lid, 2°, bedoelde inbreng is vanaf 2010 beperkt tot maximaal 5% van het
onbestemde deel van het Bijzonder Onderzoeksfonds.
Artikel 6, § 1, en artikel 8, 7° zijn niet van toepassing op de Methusalem-financiering.
§ 6. Voor de uitvoering van de Methusalem-financiering kunnen de universiteiten
overheadkosten aanrekenen tot een maximum van 10 %.
[[De overheadkosten kunnen worden besteed aan de vergoeding van kosten (werkingskosten
en loonkosten) die rechtstreeks verbonden zijn aan het beheer van de ten laste van de
Methusalemmiddelen bekostigde onderzoeksprojecten, of aan de vergoeding van centrale
beheerskosten en algemene exploitatiekosten van de universiteit.]]
Afdeling 3. - Voorwaarden voor de financiering
Art. 14quater.
§ 1. De Vlaamse universiteiten zijn belast met het operationeel en financieel beheer van de
Methusalem-financiering.
§ 2. Elke universiteit legt de voorwaarden van de Methusalem-financiering in een reglement
vast. Dit reglement werkt de nadere regelen uit met betrekking tot :
1° de organisatie van de oproep, als bedoeld in artikel 14quinquies ;
2° de eisen waaraan kandidaten moeten voldoen, als bedoeld in artikel 14sexies ;
3° de selectieprocedure, als bedoeld in artikel 14septies ;
66
4° de evaluatie, als bedoeld in artikel 14octies ;
5° de procedure voor beëindiging, als bedoeld in artikel 14novies.
Art. 14quinquies.
§ 1. De universiteit die de procedure start voor de toekenning van Methusalem-financiering
door middel van het lanceren van een oproep, deelt dit aan de andere Vlaamse universiteiten
mee in het kader van een mogelijk overleg inzake samenwerking tussen onderzoekers uit
verschillende instellingen.
§ 2. Kandidaten-onderzoekers dienen hun aanvraag voor het bekomen van Methusalemfinanciering in bij hun universiteitsbestuur.
In de aanvraag verklaren zij uitdrukkelijk in te stemmen met een eventuele bekendmaking
conform artikel 14ter decies, § 2.
Art. 14sexies.
Kandidaten voor de Methusalem-financiering moeten :
1° aan de criteria van excellentie voldoen waaruit blijkt dat ze substantieel bijdragen aan de
ontwikkeling van hun vakgebied en hiervoor internationale erkenning genieten;
2° bewijzen dat zij meer dan andere onderzoekers bestaande financieringskanalen, zoals
GOA-, IUAP-, EU-, FWO- en IWT-financiering, hebben weten te benutten;
3° over een onderzoeksgroep beschikken met een voldoende kritische massa, zoals ondermeer
kan blijken uit het aantal postdoctorale onderzoekers dat hiervan over een langere periode
deel uitmaakt;
4° een onderzoeksplan bij de betreffende universiteit(en) indienen, dat een begroting bevat
met een indicatieve verdeling van de geplande uitgaven over een periode van zeven jaar.
Art. 14septies.
§ 1. Voor de beoordeling van de kandidaten stelt elke universiteit internationale panels samen.
De leden van deze panels zijn niet in België werkzaam en genieten een internationale
erkenning. Bij de samenstelling van de panels wordt rekening gehouden met de discipline of,
in geval van interdisciplinair onderzoek, met de disciplines waarin de kandidaten actief zijn.
In een panel dient de universiteit er naar te streven dat ten hoogsten 2/3den van het totaal
aantal leden behoren tot hetzelfde geslacht. In het geval van een samenwerkingsverband
tussen twee of meer universiteiten, zoals bedoeld in § 7, stellen de betrokken universiteiten
één enkel panel samen.
§ 2. Gemiddeld over alle panels, die een universiteit instelt, vanaf de inwerkingtreding van
deze bepaling tot eind 2009, kan ten hoogste 2/3den van het totaal aantal leden tot hetzelfde
geslacht behoren. Panels die door twee of meer universiteiten samen worden ingesteld,
worden bij deze berekening aan elk van deze universiteiten toegewezen.
67
- Annex V -
Indien een universiteit niet voldoet aan de in het eerste lid bedoelde regel, wordt voor het eerst
vanaf 2011 de overheidsbijdrage aan het BOF verminderd met 0,25 % en dit tot het jaar t
waarbij in het jaar (t-2) de instelling aan deze voorwaarde voldoet.
§ 3. De universiteit legt de samenstelling van de panels voor voorafgaand advies voor aan het
FWO. Het FWO voert een meta-beoordeling van de internationale wetenschappelijke
erkenning van de panelleden door en formuleert op grond daarvan een gemotiveerd advies.
Indien het advies afwijzend is, geeft het FWO aan op welke wijze de vastgestelde gebreken
geremedieerd kunnen worden. Slechts na positief advies van het FWO kan het panel worden
ingesteld.
§ 4. Bij de beoordeling van een aanvraag past het panel de in artikel 14quater, § 2, 2°,
bedoelde eisen toe, rekening houdend met de specificiteit van het betrokken vakgebied en
onderzoeksdomein.
Het panel maakt de wijze van toetsing inzichtelijk.
Het panel gaat tevens na of met het aangevraagde bedrag van de Methusalem-financiering de
onderzoeksgroep verder uitgebouwd kan worden tot een internationale referentiepositie. Het
panel kan in dit verband bijsturingen voorstellen.
§ 5. Het panel legt zijn bevindingen neer in een omstandig geargumenteerd advies.
§ 6. Op advies van de onderzoeksraad en eventueel andere door het universiteitsbestuur
aangeduide instanties beslist het universiteitsbestuur rekening houdend met het globale
onderzoeksbeleid van de universiteit welke kandidaten die door een panel positief werden
beoordeeld, financiering zullen ontvangen. Indien het aangevraagde bedrag aan financiering
wordt aangepast dient het instellingsbestuur rekening te houden met het advies van het panel
ter zake en zijn beslissing om hier eventueel van af te wijken te onderbouwen.
§ 7. Als twee of meer universiteiten beslissen samen financiering toe te kennen, sluiten ze een
overeenkomst af, waarin het volgende bepaald wordt :
1° de getroffen regeling voor het functioneren van het geheel;
2° het aandeel van elke instelling in de financiering;
3° de modaliteiten inzake beëindiging van de financiering overeenkomstig artikel 14octies.
Afdeling 4. - Evaluatie
Art. 14octies.
§ 1. De onderzoeker die financiering ontvangt, wordt om de zeven jaar door een panel, dat aan
de in artikel 14septies bedoelde voorwaarden voldoet, geëvalueerd.
Dit panel beoordeelt :
1° of het verrichte werk internationaal toonaangevend is en aan de verwachtingen voldoet;
68
2° het human resources beleid en in het bijzonder de mate waarin post-doctorale onderzoekers
die werken in onderzoeksgroepen van ZAP-leden die Methusalem-financiering ontvangen,
worden gestimuleerd ervaring op te doen met het opzetten van zelfstandig onderzoek;
3° of het onderzoeksplan voor de volgende zeven jaar en de aangevraagde financiering
adequaat zijn.
Het panel kan suggesties voor de ontwikkeling van het onderzoek doen.
In het geval van een samenwerkingverband tussen twee of meer universiteiten, zoals bedoeld
in artikel 14septies, § 7, wordt door de betrokken universiteiten één enkel evaluatiepanel
samengesteld.
§ 2. Op basis van de in § 1 beschreven tussentijdse evaluatie beslist het universiteitsbestuur
over de voortzetting van de financiering.
Afdeling 5. - Beëindiging van de financiering
Art. 14novies.
§ 1. Als de financiering wordt beëindigd op grond van een negatieve tussentijdse evaluatie,
worden de toegekende middelen vanaf het jaar dat de beslissing is genomen, jaarlijks
verminderd met 25 %.
Als de financiering wordt beëindigd omdat het ZAP-lid het emeritaat bereikt, worden de
toegekende middelen [[vanaf het derde jaar]] voor de beëindiging jaarlijks verminderd met 25
%.
Indien een onderzoeker, die financiering ontvangt, om andere redenen dan het emeritaat de
universiteit verlaat, duidt het instellingsbestuur een gewoon hoogleraar aan om tijdelijk als
wetenschappelijk directeur op te treden en wordt de regeling betreffende de afbouw van de
financiering, vermeld in het tweede lid, van toepassing.
§ 2. Als gevolg van de toepassing van de in § 1 beschreven geleidelijke beëindiging, wordt
een nieuwe financiering stapsgewijs opgebouwd. Met de vrijgekomen middelen kan
vervolgens een nieuwe kandidaat voor de Methusalem-financiering geselecteerd worden.
§ 3. Het bereiken van het emeritaat houdt niet in dat de betrokken universiteit de financiering
niet aan een andere onderzoeker kan toekennen, op voorwaarde dat conform artikel 14septies
blijkt dat deze aan de in artikel 14sexies vermelde criteria voldoet.
Afdeling 6. - Organisatorische elementen
Art. 14decies.
§ 1. Het ZAP-lid ontvangt, behoudens in het geval van artikel 14novies, § 1, financiering tot
aan het emeritaat. Het ZAP-lid treedt op als wetenschappelijk directeur en draagt de
eindverantwoordelijkheid voor de besteding van de onderzoeksmiddelen, het
onderzoeksbeleid en het dagelijks bestuur van de onderzoeksgroep.
69
- Annex V -
Bij een samenwerkingsverband tussen twee of meer universiteiten fungeert het ene ZAP-lid
als directeur en de andere(n) als codirecteur(s).
§ 2. De omvang van de middelen is afhankelijk van de discipline en bedraagt over de periode
van zeven jaar jaarlijks gemiddeld minstens viermaal het bedrag als bedoeld in artikel 8,
eerste lid, 2, en maximaal 2.000.000 euro per jaar.
In het geval van een samenwerkingsverband tussen twee of meer universiteiten, zoals bedoeld
in artikel 14septies, § 7, gelden bovenstaande minimum- en maximumbedragen voor de
financiering die de universiteiten samen toekennen.
§ 3. Het ZAP-lid kan de middelen besteden aan werking, personeel, uitgezonderd de
salariskosten bedoeld in § 5, en uitrusting.
§ 4. De universiteit stelt aan het ZAP-lid en zijn/haar onderzoeksgroep de nodige lokalen en
basisvoorzieningen ter beschikking.
§ 5. De universiteit betaalt de salariskosten van het ZAP-lid en eventuele andere aan de
onderzoeksgroep verbonden ZAP-leden.
Art. 14undecies.
Het toekennen van een Methusalem-financiering aan ZAP-leden sluit niet uit dat
onderzoekers die verbonden zijn aan de onderzoeksgroep van betrokken ZAP-leden middelen
verwerven van andere financieringsbronnen, in het bijzonder de middelen vermeld in artikel
1bis.
Art. 14duodecies.
§ 1. In de schoot van de onderzoeksgroep van het ZAP-lid waaraan een Methusalemfinanciering wordt toegekend, wordt een beheerscomité ingesteld. Hierin zetelen minstens de
ZAP-leden die verbonden zijn aan de onderzoeksgroep. Het ZAP-lid waaraan de financiering
wordt toegekend, fungeert als voorzitter. In het geval van een samenwerkingsverband tussen
twee of meer universiteiten, zoals bedoeld in artikel 14septies, § 7, wordt één enkel
beheerscomité ingesteld. Eén van de ZAP-leden waaraan financiering wordt toegekend,
fungeert als voorzitter en de/het andere ZAP-lid/leden waaraan financiering wordt toegekend
als co-voorzitter.
§ 2. Het beheerscomité staat in voor het bestuur van de onderzoeksgroep(en), inzonderheid
voor het uitstippelen van het wetenschappelijk beleid van de onderzoeksgroep(en).
§ 3. De onderzoeksgroep of, in geval van een samenwerkingsverband, de onderzoeksgroepen,
stelt/stellen eveneens een adviesraad in, waarin onderzoekers die in het betrokken vakgebied
internationale erkenning genieten zetelen. Deze adviesraad geeft onder meer ondersteuning bij
het uitstippelen van het langetermijnonderzoeksbeleid en het vaststellen van prioriteiten in de
onderzoeksagenda.
Afdeling 7. - Rapportering
Art. 14ter decies.
70
§ 1. Artikel 12, § 1, § 2 en § 3 is van toepassing op de Methusalem-financiering.
Het jaarverslag bevat voor wat betreft de Methusalem-financiering minstens :
1° een overzicht van de gefinancierde initiatieven;
2° een toetsing van de stand van uitvoering van de gefinancierde initiatieven;
3° de eventuele bijsturing van de gefinancierde initiatieven.
§ 2. Het universiteitsbestuur publiceert op haar website de gemotiveerde beslissing van het
universiteitsbestuur, bedoeld in artikel 14septies, § 7, ten aanzien van de geselecteerde
kandidaat.
Tevens worden de beslissingen over de voortzetting van de financiering, bedoeld in artikel
14octies, § 2, gepubliceerd op de website van de universiteit.
In geval van een samenwerkingsovereenkomst wordt deze eveneens op de website van de
betrokken universiteiten gepubliceerd. Ter zake kunnen de universiteiten beslissen om een
gemeenschappelijke website te gebruiken.
Art. 14quater decies.
Om het verloop van de Methusalem-financiering systematisch te volgen, zullen de
universiteiten jaarlijks aan de Minister, bevoegd voor het wetenschappelijk onderzoek en het
technologisch innovatiebeleid, rapporteren over de volgende set van statistische parameters :
1° de verhouding tussen het aantal ingediende en gehonoreerde aanvragen (in aantal en in
budget, wetenschapsgebied, nationaliteit (Belgisch, EU, niet-EU) en geslacht;
2° de verhouding tussen de aangevraagde en de toegekende kredieten bij geselecteerde
voorstellen.]
B.Vl.R. 8-12-2006; [[ ]] B.Vl.R. 12-12-2008
71
- Annex V -
72
ANNEXVI:Personnellistanno2011
Naam Afdeling
FTE
Graad
1 Abainenamar, Doreen
Censtat 1.00
BAP
2 Abrams, Steven Censtat 1.00
BAP
Medische microbiologie
Censtat Vaccinologie
Hematologie
Huisartsgeneeskunde
Censtat Hematologie
Vaccinologie
1.00
1.00
1.00
1.00
0.80
1.00
1.00
1.00
BAP
ZAP
BAP
BAP
BAP
BAP
ZAP
ZAPBOF
11 Bielen,Kenny Medische microbiologie
1.00
BAP
12 Bilcke,Joke Vaccinologie
0.90
BAP
13 Blommaert,Adriaan Vaccinologie
1.00
BAP
14 Bontenakel,Aline Vaccinologie
1.00
ATP
15 16 17 18 19 20 21 22 23 24 25 Vaccinologie
Censtat Censtat Censtat Medische microbiologie
Censtat 1.00
1.00
1.00
1.00
0.80
1.00
0.70
0.70
1.00
0.50
1.00
BAP
ZAP
ATP
BAP
ATP
ATP
ZAP
ATP
BAP
ATP
BAP
26 Claesen, Jurgen Censtat 1.00
BAP
27 Clement, Lieven Censtat 0.15
BAP
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 Huisartsgeneeskunde
Hematologie
Censtat Hematologie
Vaccinologie
Hematologie
Vaccinologie
Hematologie
Vaccinologie
Censtat VAXINFECTIO
Censtat Censtat Hematologie
Censtat Medische microbiologie
Censtat Vaccinologie/Censtat
0.10
1.00
1.00
0.80
0.80
1.00
1.00
1.00
1.00
1.00
0.80
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
ZAP
BAP
BAP
ATP
BAP
BAP
BAP
BAP
BAP
ATP
ATP
BAP
ATP
BAP
ZAP
BAP
BAP
BAP
AAP
BAP
48 Goossens,Herman Medische microbiologie
1.00
ZAP
49 Grouwels, Yves Censtat 1.00
BAP
50 Habteab Ghebretinsae, Aklilu Censtat 1.00
BAP
51 Haldermans, Philippe
Censtat 0.70
BAP
52 Hanquet,Germaine Vaccinologie
1.00
BAP
53 Hendrickx,Greet Vaccinologie
1.00
ATP
3 4 5 6 7 8 9 10 Adriaenssens,Niels Aerts, Marc Andraud,Mathieu Anguille,Sébastien Anthierens Sibyl Azmon, Amin Berneman,Zwi Beutels,Philippe Braeckman,Tessa Braekers, Roel Broodhaers,Serge Bruckers, Liesbeth Bruynseels,An Bryssinck,Liesbeth Burzykowski, Tomasz
Callaert, Kris Castro Sanchez, Amparo Chapelle,Sabine Chebon, Sammy Coenen,Samuel Cools,Nathalie Creemers, An Daans,Jasmijn De Coster,Ilse De Knop,Kathleen De Vos,Beatrice Deckx,Nathalie Del Fava, Emanuele Desloovere,Hilde Dighou,Naïma Ejigu, Bedilu Engelen,Emmy Ensoy, Chellafe Faes, Christel Gadisseur,Alain Garcia Barrado, Leandro Gazin,Muriel Geerdens, Candida Goeyvaerts,Nele 73
- Annex VI -
Naam 54 Hens,Niel 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 74
Hoornaert,Chloé Hutse,Veronik Ieven,Margareta Janssen, Paul Jaspers, Stijn Khamiakova, Tatsiana
Lammens,Christine Lee,Wai Ping Lenders,Kevin Leten,Gert Leuridan,Elke Lion,Eva Lin, Dan Loens,Katherine Luyten,Jeroen Malhotra,Surbhi Meng, Fei Milanzi, Elasma Minalu Ayele, Girma
Molenberghs, Geert
Moons,Pieter Mutambanengwe, Chenjerai Muylle,Ludo M M A Mzolo, Thembile Neels,Pieter Neyens, Thomas Nijs,Griet Njagi, Edmund Nuyts,Amber Nys,Sophie Nysen, Ruth Ogunjimi,Benson Otava, Martin Paasch,Fabienne Perualila Nolen, Joy Pirard, Hilde Ponsaerts,Peter Prenen, Leen Quisquater,Charlotte
Reekmans,Kristien Sabbe,Martine Schroyens,Wilfried Shkedy, Ziv Smits,Evelien Sotto, Cristina Stein,Barbara Struyven,Anne Suykens,Leen Teshome Ayele, Birhanu Theeten,Heidi Thijs, Herbert Thilakarathne, Pushpike Van Damme,Pierre Van de Velde,Ann Van Den Eynde,Sandy
Van Der Planken,Marc
Van Heirstraeten,Liesbet Afdeling
FTE
Graad
Vaccinologie/Censtat
1.00
ZAP
Hematologie
Vaccinologie
Censtat Censtat Censtat Medische microbiologie
Hematologie
Hematologie
Vaccinologie
Hematologie
Vaccinologie
Censtat Censtat Censtat Censtat Medische microbiologie
Censtat Hematologie
Censtat Hematologie
Censtat Hematologie
VAXINFECTIO
Censtat Censtat Hematologie
Censtat Hematologie
Hematologie
Vaccinologie
Hematologie
Censtat Hematologie
Vaccinologie
Censtat Censtat Vaccinologie
Hematologie
Hematologie
Hematologie
1.00
1.00
0.10
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.95
0.80
1.00
1.00
1.00
1.00
1.00
0.70
1.00
1.00
0.25
1.00
1.00
1.00
1.00
1.00
1.00
0.80
1.00
1.00
1.00
1.00
1.00
1.00
0.90
1.00
1.00
1.00
1.00
0.10
1.00
1.00
1.00
1.00
0.80
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
BAP
BAP
ZAP
ZAP
AAP
BAP
ATP
BAP
ATP
ATP
AAP
BAP
BAP
BAP
BAP
ZAPBOF
BAP
BAP
BAP
ZAP
BAP
BAP
BAP
BAP
BAP
AAP
BAP
BAP
BAP
ATP
AAP
BAP
BAP
BAP
BAP
ATP
BAP
AAP
BAP
BAP
BAP
ZAP
ZAP
BAP
BAP
BAP
ATP
BAP
BAP
AAP
BAP
BAP
ZAP
BAP
BAP
BAP
BAP
112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 Naam Afdeling
FTE
Graad
Van Herck,Koen Van Kerckhove,Kim Van kerckhoven,Margaretha Van Tendeloo,Vigor F I
Van Winckel,Anna Vandendijck, Yannick
Vanderstraeten,Anouk
Vankerckhoven,Vanessa Vercauteren,Greetje
Verheyen,Els Vermeulen,Katrien Versporten,Ann Vervoort,Jascha Verwimp,Gino Vorsters,Alex Vrelust,Inge Wami, Welcome Wijdooghe,Monique
Willem,Lander Willemen,Yannick Yildirim,Perihan Zamanzad Ghavidel, Fatemeh Vaccinologie
Hematologie
Vaccinologie
VAXINFECTIO
Vaccinologie
Hematologie
ESOC Vaccinologie
VAXINFECTIO
Vaccinologie
Hematologie
VAXINFECTIO
Censtat 0.10
1.00
0.80
1.00
1.00
1.00
0.50
1.00
1.00
0.90
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.53
1.00
1.00
1.00
1.00
ZAP
AAP
ATP
ZAPBOF
ATP
BAP
ATP
BAP
ATP
ATP
BAP
BAP
BAP
ATP
ATP
BAP
BAP
ATP
BAP
BAP
BAP
BAP
1.00
BAP
134 Zarb, Peter 75
- Annex VI -
76
ANNEXVII:ListofongoingProjects2011
77
23/01/2012
Faculteit :
1
Faculteit Geneeskunde en Gezondheidswetenschappen
Departement :
Vaccin & infectieziekten instituut
Team : VAXINFECTIO
Titel project :
Ondersteuning van de activiteiten van de Viral Hepatitis Prevention Board (VHPB).
Looptijd :
van
01/01/2000
tot
31/12/2012
Type Project :
van
van
van
Van Damme Pierre
Meheus Andre
Van Damme Pierre
Promotor :
Promotor :
Co-promotor :
Id :
3205
Onderzoeksproject
01/10/2004
01/01/2000
01/01/2000
tot
tot
tot
31/12/2012
30/09/2004
30/09/2004
Fin.programma :
302100006
302100006
302100006
302100025
302100025
302100025
302100025
302100025
302100054
302100054
302100054
302100054
302100054
302100054
302100054
302100079
302100079
800100024
800100024
800100024
800100024
800100024
800100024
800100024
800100024
800100024
800100053
800100053
Aventis
Aventis
Aventis
Merck
Merck
Merck
Merck
Merck
Sanofi Pasteur MSD
Sanofi Pasteur MSD
Sanofi Pasteur MSD
Sanofi Pasteur MSD
Sanofi Pasteur MSD
Sanofi Pasteur MSD
Sanofi Pasteur MSD
Sanofi Pasteur SA
Sanofi Pasteur SA
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
SmithKline Beecham
SmithKline Beecham
01/01/2005
01/01/2004
01/01/2003
01/01/2008
01/01/2011
01/01/2010
01/01/2003
01/01/2012
01/01/2006
01/01/2008
01/01/2011
01/01/2007
01/01/2009
01/09/2006
01/01/2010
09/03/2010
01/02/2011
01/01/2003
01/01/2009
01/01/2004
01/01/2006
01/01/2007
01/01/2011
01/01/2010
01/01/2002
01/01/2005
01/01/2000
01/01/2001
Budget : €
Titel project :
Gentherapie : van gentransfer tot klinische toepassingen.
Looptijd :
van
Promotor :
01/01/2002
tot
31/12/2011
Berneman Zwi
31/12/2005
31/12/2004
31/12/2003
31/12/2008
31/12/2011
31/12/2010
31/12/2003
31/12/2012
31/12/2006
31/12/2009
31/12/2011
31/12/2007
31/12/2009
31/12/2009
31/12/2010
31/12/2010
31/12/2011
31/12/2003
31/12/2009
31/12/2004
31/12/2006
31/12/2007
31/12/2012
31/12/2010
31/12/2002
31/12/2005
31/12/2000
31/12/2001
4.524.546,08
Id :
Type Project :
van
3868
Samenwerkingsverband
Onderzoeksproject
01/01/2002
tot
31/12/2011
Fin.programma :
7005
7005
FWO wetenschappelijke
onderzoeksgemeenschappen
01/01/2002
31/12/2006
01/01/2007
31/12/2011
Budget : €
23.042,00
23/01/2012
Faculteit :
2
Departement :
Team : VAXINFECTIO
Titel project :
Genetica als hulpmiddel in de strijd tegen antibiotica resistentie bij lage luchtweg infecties
in Europa. (GRACE)
Looptijd :
van
01/03/2006
tot
31/08/2011
Type Project :
van
van
Goossens Herman
Coenen Samuel
Promotor :
Co-promotor :
Id :
20774
Onderzoeksproject
01/03/2006
01/03/2006
tot
tot
31/08/2011
31/08/2011
Fin.programma :
EU KP6: LIFE (Biowetenschappen, genomica en
biotechnologie voor de gezondheid)
3601
01/03/2006
Budget : €
Titel project :
Inhibitie van HIV-replicatie.
Looptijd :
van
01/01/2007
tot
1.581.451,00
Id :
31/12/2011
Type Project :
van
van
van
Berneman Zwi
Vanham Guido
Van Tendeloo Vigor F I
Promotor :
Co-promotor :
Co-promotor :
31/08/2011
21357
Onderzoeksproject
01/01/2007
01/01/2007
01/01/2007
tot
tot
tot
31/12/2011
31/12/2011
31/12/2011
Fin.programma :
4106
4106
4106
4106
4106
IUAP-VI (1/1/2007-31/12/2011)
IUAP-VI (1/1/2007-31/12/2011)
IUAP-VI (1/1/2007-31/12/2011)
IUAP-VI (1/1/2007-31/12/2011)
IUAP-VI (1/1/2007-31/12/2011)
01/01/2007
01/01/2010
01/01/2008
01/01/2009
01/01/2011
31/12/2007
31/12/2010
31/12/2008
31/12/2009
31/12/2011
Budget : €
Titel project :
Beheer van antimicrobiële resistentie in het ziekenhuis en de verspreiding in de
gemeenschap. (MOSAR)
Looptijd :
van
01/02/2007
tot
31/01/2012
Type Project :
van
Goossens Herman
Promotor :
800.000,00
Id :
22204
Onderzoeksproject
01/02/2007
tot
31/01/2012
Fin.programma :
EU KP6: LIFE (Biowetenschappen, genomica en
biotechnologie voor de gezondheid)
3601
01/02/2007
Budget : €
Titel project :
Simulatiemodellen van transmissie van besmettelijke ziekten en controle processen
(SIMID).
Looptijd :
van
Promotor :
01/03/2007
tot
28/02/2011
Beutels Philippe
Type Project :
van
31/01/2012
542.962,00
Id :
21539
Onderzoeksproject
01/03/2007
tot
28/02/2011
Fin.programma :
5020
SBO (Strategisch Basisonderzoek)
01/03/2007
Budget : €
28/02/2011
1.035.000,00
23/01/2012
Faculteit :
3
Departement :
Team : VAXINFECTIO
Titel project :
Gedragsverandering van zorgverleners en publiek naar een meer voorzichtig gebruik van
anti-microbiële agentia (CHAMP).
Looptijd :
van
01/04/2007
tot
31/03/2011
Type Project :
van
van
Goossens Herman
Coenen Samuel
Promotor :
Co-promotor :
Id :
21868
Onderzoeksproject
01/04/2007
01/04/2007
tot
tot
31/03/2011
31/03/2011
Fin.programma :
EU KP6: Beleidsondersteunend onderzoek en
NEST
3608
01/04/2007
31/03/2011
Budget : €
Titel project :
Wetenschappelijke evaluatie van de consumptie van antibiotica voor menselijk gebruik
(ESAC-3).
Looptijd :
van
03/09/2007
tot
01/07/2011
Type Project :
van
Goossens Herman
Promotor :
94.392,00
Id :
21911
Onderzoeksproject
03/09/2007
tot
01/07/2011
Fin.programma :
389900003
389900003
389900003
389900003
European Centre for Disease Prevention and
Control (ECDC)
Control (ECDC)
Control (ECDC)
Control (ECDC)
03/09/2008
02/09/2009
02/09/2010
01/07/2011
03/09/2007
02/09/2008
03/09/2009
02/09/2010
Budget : €
Titel project :
Cellulaire immunologie in kanker en AIDS, en multidisciplinair celtherapie-onderzoek en
klinische studies.
Looptijd :
van
01/10/2007
tot
30/09/2012
Promotor :
Mandaathouder :
Type Project :
van
van
2.199.319,00
Id :
22897
Onderzoeksproject
01/10/2007
01/10/2007
tot
tot
30/09/2012
30/09/2012
Fin.programma :
5413
ZAP BOF-mandaten
01/10/2007
Budget : €
Titel project :
Oprichting van een translationeel platform voor geïntegreerd vaccinonderzoek.
Looptijd :
van
Promotor :
Co-promotor :
Co-promotor :
01/12/2007
tot
26/11/2012
Van Damme Pierre
Berneman Zwi
Goossens Herman
Type Project :
van
van
van
30/09/2012
400.000,00
Id :
21972
Onderzoeksproject
01/12/2007
01/12/2007
01/12/2007
tot
tot
tot
26/11/2012
26/11/2012
26/11/2012
Fin.programma :
5431
800100024
IOF - Industrieel Onderzoeksfonds
GlaxoSmithKline
01/12/2007
27/11/2008
Budget : €
30/11/2011
26/11/2012
660.000,00
23/01/2012
Faculteit :
4
Departement :
Team : VAXINFECTIO
Titel project :
Effect van innate immuunsignalen op leukemische cellen voor de stimulatie van natural
killercellen en T helper 1-polariserende dendritische cellen.
Looptijd :
van
01/01/2008
tot
31/12/2011
Berneman Zwi
Promotor :
Co-promotor :
Type Project :
van
van
Id :
21884
Onderzoeksproject
01/01/2008
01/01/2008
tot
tot
31/12/2011
31/12/2011
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2010
01/01/2009
01/01/2008
01/01/2011
Budget : €
120.000,00
Titel project :
Het beleid van lage luchtweginfecties in de huisartsenpraktijk optimaliseren op basis van
etiologisch, diagnostisch, prognostisch en interventie-onderzoek.
Looptijd :
van
01/01/2008
tot
31/12/2011
Goossens Herman
Coenen Samuel
Van Royen Paul
Promotor :
Co-promotor :
Co-promotor :
Type Project :
van
van
van
31/12/2010
31/12/2009
31/12/2008
31/12/2011
Id :
21931
Onderzoeksproject
01/01/2008
01/01/2008
01/01/2008
tot
tot
tot
31/12/2011
31/12/2011
31/12/2011
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2010
01/01/2009
01/01/2008
01/01/2011
Budget : €
Titel project :
Mechanismen van protectieve immuniteit bij HIV-1 geïnfecteerde personen na een
periode van antiretrovirale therapie.
Looptijd :
van
01/01/2008
tot
31/12/2011
van
Berneman Zwi
Promotor :
Type Project :
31/12/2010
31/12/2009
31/12/2008
31/12/2011
349.561,00
Id :
21947
Onderzoeksproject
01/01/2008
tot
31/12/2011
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2010
01/01/2009
01/01/2008
01/01/2011
Budget : €
Titel project :
Niet-invasieve beeldvorming van migratie en overleving van stamcellen in de hersenen
(BRAINSTIM).
Looptijd :
van
Promotor :
01/01/2008
tot
31/12/2011
Berneman Zwi
Type Project :
van
31/12/2010
31/12/2009
31/12/2008
31/12/2011
40.000,00
Id :
22338
Onderzoeksproject
01/01/2008
tot
31/12/2011
Fin.programma :
5020
SBO (Strategisch Basisonderzoek)
01/01/2008
Budget : €
31/12/2011
381.187,00
23/01/2012
Faculteit :
5
Departement :
Team : VAXINFECTIO
Titel project :
Geïntegreerd onderzoek naar vaccins en infectieziekten.
Looptijd :
van
01/01/2008
tot
31/12/2014
Type Project :
van
van
van
Goossens Herman
Van Damme Pierre
Berneman Zwi
Promotor :
Co-promotor :
Co-promotor :
Id :
22858
Onderzoeksproject
tot
tot
tot
01/01/2008
01/01/2008
01/01/2008
31/12/2014
31/12/2014
31/12/2014
Fin.programma :
541200024
541200024
5416
5416
BOF: Onderzoeksexcellentiecentra
BOF: Onderzoeksexcellentiecentra
Methusalem
Methusalem
01/01/2008
01/01/2009
01/01/2009
01/01/2008
Budget : €
Titel project :
Een geïntegreerd platform dat theranostische toepassingen mogelijk maakt in de
eerstelijn gezondheiszorg. (TheraEdge)
Looptijd :
van
01/03/2008
tot
29/02/2012
Type Project :
van
Goossens Herman
Promotor :
31/12/2008
31/12/2014
31/12/2014
31/12/2008
2.990.000,00
Id :
22760
Onderzoeksproject
01/03/2008
tot
29/02/2012
Fin.programma :
EU KP7: Informatie- &
Communicatietechnologieën
3703
01/03/2008
Budget : €
491.202,25
Titel project :
Een sterk geïntegreerde optische sensor voor point of care identificatie van bacteriën die
sepsis veroorzaken en bepaling van het antibiotica resistentieprofiel. ( InTopSens)
Looptijd :
van
01/09/2008
tot
31/08/2011
Type Project :
van
van
Goossens Herman
Malhotra Surbhi
Promotor :
Co-promotor :
29/02/2012
Id :
23028
Onderzoeksproject
01/09/2008
01/09/2008
tot
tot
31/08/2011
31/08/2011
Fin.programma :
EU KP7: Informatie- &
Communicatietechnologieën
3703
01/09/2008
Budget : €
Titel project :
Druggebruik onder vrouwelijke sekswerkers in België (DRUSEB).
Looptijd :
van
Promotor :
01/10/2008
tot
31/12/2011
Type Project :
Van Damme Pierre
van
31/08/2011
195.410,00
Id :
23450
Onderzoeksproject
01/10/2008
tot
31/12/2011
Fin.programma :
4243
Onderzoeksprogramma ter ondersteuning van de
federale beleidsnota Drugs (DR)
01/10/2008
Budget : €
31/12/2011
5.028,68
23/01/2012
Faculteit :
6
Departement :
Team : VAXINFECTIO
Titel project :
Dubbelblind, gerandomiseerd onderzoek naar de immunogeniciteit en de reactogeniciteit
van het geïnactiveerde vaccin tegen hepatitis A - dat 1440 El.U antigen bevat per ml, en
dat wordt geïnjecteerd volgens een 0-12 maanden vaccinatieschema.
Looptijd :
van
28/10/2008
tot
31/01/2013
Type Project :
van
van
Van Damme Pierre
Van Herck Koen
Promotor :
Co-promotor :
Id :
23165
Onderzoeksproject
tot
tot
28/10/2008
28/10/2008
31/01/2013
31/01/2013
Fin.programma :
800100024
GlaxoSmithKline
28/10/2008
Budget : €
179.900,08
Titel project :
Dubbelblind, gerandomiseerd onderzoek naar de immunogeniciteit en de reactogeniciteit
van het geïnactiveerde vaccin tegen hepatitis A - dat 1440 El.U antigen bevat per ml, en
dat wordt geïnjecteerd volgens een 0-6 maanden vaccinatieschema.
Looptijd :
van
28/10/2008
tot
31/01/2013
Type Project :
van
van
Van Damme Pierre
Van Herck Koen
Promotor :
Co-promotor :
31/01/2013
Id :
23166
Onderzoeksproject
tot
tot
28/10/2008
28/10/2008
31/01/2013
31/01/2013
Fin.programma :
800100024
GlaxoSmithKline
28/10/2008
Budget : €
108.513,41
Titel project :
Highspeed, fixed alignment benchtop cell sorter platform. (Becton Dickinson FACSAria II)
Looptijd :
van
19/12/2008
tot
18/12/2013
Type Project :
van
van
van
van
Berneman Zwi
Ebo Didier
Stevens Willem
Promotor :
Co-promotor :
Co-promotor :
Co-promotor :
31/01/2013
Id :
23709
Onderzoeksproject
tot
tot
tot
tot
19/12/2008
19/12/2008
19/12/2008
19/12/2008
18/12/2013
18/12/2013
18/12/2013
18/12/2013
Fin.programma :
Eigen Middelen zoals patrimonium,
inschrijvingsgelden, giften, ....
Hercules: Kleine en Middelzware apparatuur
1000
7710
19/12/2008
18/12/2013
19/12/2008
18/12/2013
Budget : €
Titel project :
Klinisch en preklinisch onderzoek naar het effect van cellulaire mediatoren op het
bijsturen van pathogene responsen in multiple sclerose.
Looptijd :
van
Promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Co-promotor :
01/01/2009
tot
31/12/2012
Ysebaert Dirk
Ponsaerts Peter
Cras Patrick
Berneman Zwi
Cools Nathalie
Type Project :
van
van
van
van
van
van
434.966,00
Id :
22727
Onderzoeksproject
01/01/2009
01/01/2009
01/01/2009
01/01/2009
01/01/2009
01/01/2009
tot
tot
tot
tot
tot
tot
31/12/2012
31/12/2012
31/12/2012
31/12/2012
31/12/2012
31/12/2012
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2010
01/01/2009
01/01/2012
01/01/2011
Budget : €
31/12/2010
31/12/2009
31/12/2012
31/12/2011
347.200,00
23/01/2012
Faculteit :
7
Departement :
Team : VAXINFECTIO
Titel project :
Onderzoek naar Antibiotica Resistentie Mechanismen die een Ketoliden en
Fluoroquinolonen resistentie van hoog niveau mediëren in Streptococcus pyogenes.
Looptijd :
van
01/01/2009
tot
31/12/2011
Malhotra Surbhi
Promotor :
Type Project :
van
Id :
22840
Onderzoeksproject
01/01/2009
tot
31/12/2011
Fin.programma :
7020
FWO-kredieten aan navorser
01/01/2009
Budget : €
Titel project :
Karakterisering van immuunresponsen gericht tegen allogene stamcelimplantaten in het
centraal zenuwstelsel.
Looptijd :
van
01/01/2009
tot
31/12/2011
Ponsaerts Peter
Promotor :
Type Project :
van
31/12/2011
20.000,00
Id :
22846
Onderzoeksproject
01/01/2009
tot
31/12/2011
Fin.programma :
7020
01/01/2009
Budget : €
Titel project :
Belgisch multidisciplinair HIV onderzoek.
Looptijd :
van
01/01/2009
tot
31/12/2013
10.000,00
Id :
Type Project :
van
Berneman Zwi
Promotor :
31/12/2011
23360
Onderzoeksproject
01/01/2009
tot
31/12/2013
Fin.programma :
7005
01/01/2009
Budget : €
Titel project :
Leerstoel "Evidence Based Vaccinology".
Looptijd :
van
01/01/2009
tot
31/12/2011
Beutels Philippe
Van Damme Pierre
Promotor :
Co-promotor :
31/12/2013
8.929,00
Id :
Type Project :
van
van
23750
Onderzoeksproject
01/01/2009
01/01/2009
tot
tot
31/12/2011
31/12/2011
Fin.programma :
800000050
Handgiften
01/01/2009
Budget : €
Titel project :
Gezondheidseconomie.
Looptijd :
van
Promotor :
Mandaathouder :
01/01/2009
31/12/2011
180.000,00
Id :
tot
31/12/2013
Beutels Philippe
Beutels Philippe
Type Project :
van
van
23897
Onderzoeksproject
01/01/2009
01/01/2009
tot
tot
31/12/2013
31/12/2013
Fin.programma :
5413
ZAP BOF-mandaten
01/01/2009
Budget : €
31/12/2013
425.000,00
23/01/2012
Faculteit :
8
Departement :
Team : VAXINFECTIO
Titel project :
A Rising Single Dose, Double-Blind, Randomized, Placebo- Controlled Study to Evaluate
Safety, Tolerability and Immunogenicity of SCH 900795 in Healthy Adults P05653-01.
Looptijd :
van
01/02/2009
tot
31/01/2011
Van Damme Pierre
Promotor :
Type Project :
van
Id :
23509
Onderzoeksproject
01/02/2009
tot
31/01/2011
Fin.programma :
302100034
Schering
01/02/2009
31/01/2011
Budget : €
Titel project :
Inductie van multiple sclerose (ms)-specifieke immuuntolerantie gebruikmakende van
tolerogene dendritische cellen en regulerende t-cellen.
Looptijd :
van
01/02/2009
tot
31/07/2013
Cools Nathalie
Promotor :
Co-promotor :
Type Project :
van
van
0,00
Id :
23564
Onderzoeksproject
01/02/2009
01/02/2009
tot
tot
31/07/2013
31/07/2013
Fin.programma :
800000028
Legaten
01/02/2009
Budget : €
Titel project :
VZV vaccination in children and adults aged over 50 years: health technology
assessment.
Looptijd :
van
01/06/2009
tot
15/12/2011
Beutels Philippe
Promotor :
Type Project :
van
31/07/2013
127.750,00
Id :
24104
Onderzoeksproject
01/06/2009
tot
15/12/2011
Fin.programma :
459900003
459900003
Federaal Kenniscentrum voor de
Gezondheidszorg (KCE)
31/05/2010
15/12/2011
01/06/2009
31/05/2010
Budget : €
179.645,71
Titel project :
A randomized, single-blind, dose-ranging...of adjuvanted and non adjuvanted egg-derived
inactivated novel swine rigin A/H1N1 monovalent subunit influenza virus vaccine in
healthy subjects 18 or more years of age.
Looptijd :
van
05/08/2009
tot
31/08/2011
Van Damme Pierre
Promotor :
Type Project :
van
Id :
24164
Onderzoeksproject
05/08/2009
tot
31/08/2011
Fin.programma :
302100065
Novartis Pharmaceuticals Corporation
05/08/2009
Budget : €
Titel project :
A randomized, single-blind, dose-ranging, ... of adjuvanted and non adjuvanted
cell-derived inactivated novel swine rigin A/H1N1 monovalent subunit influenza virus
vaccine in healthy subjects 18 or more years of age.
Looptijd :
van
Promotor :
05/08/2009
tot
31/08/2011
Van Damme Pierre
Type Project :
van
31/08/2011
98.280,00
Id :
24165
Onderzoeksproject
05/08/2009
tot
31/08/2011
Fin.programma :
302100065
05/08/2009
Budget : €
31/08/2011
49.140,00
23/01/2012
Faculteit :
9
Departement :
Team : VAXINFECTIO
Titel project :
Rol v/h Wilms tumor gen (WT1) als biomarker voor het voorspellen van leukemie recidief
en voor de beoordeling van de werkzaamheid van DC vaccinatie met behulp van WT1
mRNA-transfected autologe dendritische cellen van patiënten met acute myeloid
leukemie.
Looptijd :
van
01/09/2009
tot
31/08/2012
Berneman Zwi
Promotor :
Co-promotor :
Type Project :
van
van
Id :
24163
Onderzoeksproject
01/09/2009
01/09/2009
tot
tot
31/08/2012
31/08/2012
Fin.programma :
800300042
Vlaamse Liga tegen Kanker
01/09/2009
Budget : €
70.000,00
Titel project :
Het effect van cellulaire mediatoren op het bijsturen van pathogene responsen in multiple
sclerose (MS) patiënten.
Looptijd :
van
01/10/2009
tot
30/09/2012
van
van
Berneman Zwi
Cools Nathalie
Promotor :
Mandaathouder :
Type Project :
31/08/2012
Id :
23681
Onderzoeksproject
01/10/2009
01/10/2009
tot
tot
30/09/2012
30/09/2012
Fin.programma :
700300003
FWO tijdelijke mandaten: postdoct.
01/10/2009
Budget : €
Titel project :
Neurale stamcellen: moleculaire en fysiologische controle van in vivo differentiatie ,
migratie en immunogeniciteit.
Looptijd :
van
01/10/2009
tot
30/09/2012
Berneman Zwi
Ponsaerts Peter
Promotor :
Mandaathouder :
Type Project :
van
van
30/09/2012
226.026,00
Id :
23718
Onderzoeksproject
01/10/2009
01/10/2009
tot
tot
30/09/2012
30/09/2012
Fin.programma :
700300004
FWO tijdelijke mandaten: postdoct. 1ste
hernieuwing
01/10/2009
Budget : €
243.429,00
Titel project :
De geschiktheid van het voorschrijven van antibiotica in de eerstelijns gezondheidszorg in
Europa met betrekking tot resistentie tegen antibiotica (APRES).
Looptijd :
van
Promotor :
Co-promotor :
01/10/2009
tot
30/09/2013
Goossens Herman
Coenen Samuel
Type Project :
van
van
30/09/2012
Id :
24233
Onderzoeksproject
01/10/2009
01/10/2009
tot
tot
30/09/2013
30/09/2013
Fin.programma :
3701
EU KP7: Gezondheid
01/10/2009
Budget : €
30/09/2013
204.019,00
23/01/2012
Faculteit :
10
Departement :
Team : VAXINFECTIO
Titel project :
An open, single centre study to evaluate the long-term antibody persistence and immune
memory between 16 and 20 years after the primary study HAB-028 (208127/021) in which
healthy adults were vaccinated with Twinrix Adult following a three -dose schedule.
Looptijd :
van
01/10/2009
tot
31/10/2015
Van Damme Pierre
Van Herck Koen
Promotor :
Co-promotor :
Type Project :
van
van
Id :
24277
Onderzoeksproject
01/10/2009
01/10/2009
tot
tot
31/10/2015
31/10/2015
Fin.programma :
800100024
GlaxoSmithKline
01/10/2009
31/10/2015
Budget : €
Titel project :
Multidisciplinair onderzoek van vaccinatie en infectieziekten.
Looptijd :
van
01/11/2009
tot
31/10/2011
Van Damme Pierre
Berneman Zwi
Goossens Herman
Vankerckhoven Vanessa
Promotor :
Co-promotor :
Co-promotor :
Mandaathouder :
Type Project :
van
van
van
van
0,00
Id :
24341
Onderzoeksproject
01/11/2009
01/11/2009
01/11/2009
01/11/2009
tot
tot
tot
tot
31/10/2011
31/10/2011
31/10/2011
31/10/2011
Fin.programma :
543100001
IOF: Mandaten
01/11/2009
Budget : €
Titel project :
Cost-effectiveness of 7, 10 and 13-valent pneumococcal conjugate vaccines
2009-52_HTA.
Looptijd :
van
10/12/2009
tot
15/04/2011
Beutels Philippe
Van Damme Pierre
Promotor :
Co-promotor :
Type Project :
van
van
31/10/2011
170.000,00
Id :
24542
Onderzoeksproject
10/12/2009
10/12/2009
tot
tot
15/04/2011
15/04/2011
Fin.programma :
459900003
10/12/2009
Budget : €
133.705,00
Titel project :
Een fase III klinisch onderzoek naar de studie van de immunogeniciteit, verdraagbaarheid
en fabricage consistentie van de V503 in preadolescenten en adolescenten met een
vergelijking met jonge vrouwen.
Looptijd :
van
Promotor :
11/12/2009
tot
30/04/2013
Van Damme Pierre
Type Project :
van
15/04/2011
Id :
24544
Onderzoeksproject
11/12/2009
tot
30/04/2013
Fin.programma :
302100025
302100025
302100025
Merck
Merck
Merck
11/12/2010
11/12/2009
01/02/2011
Budget : €
30/04/2013
10/12/2010
30/04/2013
218.484,48
23/01/2012
Faculteit :
11
Departement :
Team : VAXINFECTIO
Titel project :
Identificatie van nieuwe aan het celoppervlak uitgedrukte factoren betrokken bij virulentie
en biofilmvervorming van methicilline-resistente Staphylococcus aureus.
Looptijd :
van
01/01/2010
tot
31/12/2012
Type Project :
van
van
Goossens Herman
Malhotra Surbhi
Promotor :
Co-promotor :
Id :
23949
Onderzoeksproject
01/01/2010
01/01/2010
tot
tot
31/12/2012
31/12/2012
Fin.programma :
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2010
01/01/2012
01/01/2011
Budget : €
Titel project :
Karakterisering van circulerende dendritische cellen (DC) in multiple sclerose (MS):
bepaling van subtypes en functionaliteit.
Looptijd :
van
01/01/2010
tot
31/12/2011
Type Project :
van
Cools Nathalie
Promotor :
31/12/2010
31/12/2012
31/12/2011
60.000,00
Id :
24275
Onderzoeksproject
01/01/2010
tot
31/12/2011
Fin.programma :
541200005
BOF: Kleine projecten onderzoeksraad
01/01/2010
Budget : €
7.500,00
Titel project :
In vivo niet-invasieve beeldvorming van acute myeloide leukemie (AML) immunotherapie
bij muizen.
Looptijd :
van
01/01/2010
tot
31/12/2011
Type Project :
van
Smits Evelien
Promotor :
31/12/2011
Id :
24343
Onderzoeksproject
01/01/2010
tot
31/12/2011
Fin.programma :
541200005
01/01/2010
Budget : €
Titel project :
Maternele immuniteit in het puerperium
Looptijd :
van
01/01/2010
tot
31/12/2011
7.500,00
Id :
Type Project :
van
Loens Katherine
Promotor :
31/12/2011
24378
Onderzoeksproject
01/01/2010
tot
31/12/2011
Fin.programma :
541200005
01/01/2010
Budget : €
Titel project :
Multiple Sclerose, een multidisciplinaire benadering.
Looptijd :
van
Promotor :
01/01/2010
tot
31/12/2014
Berneman Zwi
31/12/2011
7.500,00
Id :
Type Project :
van
24405
Onderzoeksproject
01/01/2010
tot
31/12/2014
Fin.programma :
7005
01/01/2010
Budget : €
31/12/2014
5.682,00
23/01/2012
Faculteit :
12
Departement :
Team : VAXINFECTIO
Titel project :
Impact van specifieke antibiotische therapie op de prevalentie van resistente bacteriën
van een menselijke gastheer (SATURN).
Looptijd :
van
01/01/2010
tot
31/12/2014
Type Project :
van
van
van
Goossens Herman
Coenen Samuel
Malhotra Surbhi
Promotor :
Co-promotor :
Co-promotor :
Id :
24575
Onderzoeksproject
01/01/2010
01/01/2010
01/01/2010
tot
tot
tot
31/12/2014
31/12/2014
31/12/2014
Fin.programma :
3701
EU KP7: Gezondheid
01/01/2010
Budget : €
1.019.930,00
Titel project :
A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V 503,
a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given
Concomitantly With REPEVAX in Preadolescents and Adolescents.
Looptijd :
van
22/01/2010
tot
21/01/2011
Type Project :
van
Van Damme Pierre
Promotor :
31/12/2014
Id :
25172
Onderzoeksproject
22/01/2010
tot
21/01/2011
Fin.programma :
302100025
Merck
22/01/2010
Budget : €
91.381,21
Titel project :
In vivo niet-vasieve beeldvorming van acute myeloide leukemie (AML) immunotherapie bij
muizen.
Looptijd :
van
01/02/2010
tot
31/12/2012
Type Project :
van
Smits Evelien
Promotor :
21/01/2011
Id :
24948
Onderzoeksproject
01/02/2010
tot
31/12/2012
Fin.programma :
800400018
Stichting Rosa Blanckaert - Aanmoedigingsbeurs
jonge vorsers
01/02/2010
Budget : €
2.500,00
Titel project :
A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the
Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine against S . Typhi in Adult
Subjects 18 to 40 Years of Age.
Looptijd :
van
02/03/2010
tot
01/03/2011
Van Damme Pierre
Promotor :
Type Project :
van
31/12/2012
Id :
24961
Onderzoeksproject
02/03/2010
tot
01/03/2011
Fin.programma :
302100065
02/03/2010
Budget : €
Titel project :
A phase IV, open, non-randomized, multicentre study to assess the reactogenicity and
immunogenicity of a booster dose of GSK ... in study 263855/029 (dTpa-029).
Looptijd :
van
Promotor :
01/05/2010
tot
31/03/2012
Van Damme Pierre
Type Project :
van
01/03/2011
64.017,38
Id :
25298
Onderzoeksproject
01/05/2010
tot
31/03/2012
Fin.programma :
800100024
GlaxoSmithKline
01/05/2010
Budget : €
31/03/2012
22.550,00
23/01/2012
Faculteit :
13
Departement :
Team : VAXINFECTIO
Titel project :
Tolerance and Immunogenicity of ProCervix, an adjuvanted therapeutic vaccine
composed of 2 recombinant adenylate cyclases, in HPV 16 and/or 18 infected women
with normal cytology.
Looptijd :
van
01/06/2010
tot
31/03/2011
Type Project :
van
Promotor :
Id :
25324
Dienstverleningsproject
Onderzoeksproject
tot
01/06/2010
31/03/2011
Fin.programma :
302100080
Genticel
01/06/2010
Budget : €
Titel project :
Ondersteuning van de puntprevalentiestudie van gezondheidszorg-geassocieerde
infecties en antimicrobieel gebruik in Europese ziekenhuizen.
Looptijd :
van
01/06/2010
tot
31/03/2011
Type Project :
van
Goossens Herman
Promotor :
31/03/2011
67.525,38
Id :
25335
Onderzoeksproject
01/06/2010
tot
31/03/2011
Fin.programma :
389900003
Control (ECDC)
01/06/2010
Budget : €
Titel project :
Tolerance and immunogenicity of ProCervix, an adjuvanted therapeutic vaccine
Looptijd :
van
26/07/2010
tot
25/07/2011
Type Project :
van
van
Van Damme Pierre
Hens Annick
Promotor :
Co-promotor :
31/03/2011
130.000,00
Id :
25408
Onderzoeksproject
26/07/2010
26/07/2010
tot
tot
25/07/2011
25/07/2011
Fin.programma :
302100080
Genticel
26/07/2010
Budget : €
Titel project :
Antibiotic resistance and prescribing in European Children (ARPEC).
Looptijd :
van
01/09/2010
tot
31/08/2013
Type Project :
van
Goossens Herman
Promotor :
25/07/2011
3.000,00
Id :
25413
Onderzoeksproject
01/09/2010
tot
31/08/2013
Fin.programma :
3899
EU: Andere Eu-initiatieven buiten kader
01/09/2010
Budget : €
101.569,13
Titel project :
A Phase 2, Randomized, observer-blind, Controlled, Single Center Study to Evaluate the
Safety and Immunogenicity of three formulations of the NVGH Glycoconjugate Vaccine
against S. Typhi in Adult Subjects 18 to 40 Years of Age.
Looptijd :
van
Promotor :
01/09/2010
tot
28/02/2011
Type Project :
Van Damme Pierre
van
31/08/2013
Id :
25434
Onderzoeksproject
01/09/2010
tot
28/02/2011
Fin.programma :
302100083
Novartis Vaccines Institute for Global Health
01/09/2010
Budget : €
28/02/2011
76.336,40
23/01/2012
Faculteit :
14
Departement :
Team : VAXINFECTIO
Titel project :
RHAMM als een aantrekkelijk immunotherapeutisch doelwitantigen voor dendritische
cel-geïnduceerde T-cel immuniteit gericht tegen leukemie en myeloom.
Looptijd :
van
01/10/2010
tot
30/12/2011
Berneman Zwi
Willemen Yannick
Promotor :
Mandaathouder :
Type Project :
van
van
Id :
24697
Onderzoeksproject
01/10/2010
01/10/2010
tot
tot
30/12/2011
30/12/2011
Fin.programma :
541200003
541200004
BOF: Opvangmandaten FWO
BOF: Opvangmandaten IWT
01/10/2010
01/10/2011
Budget : €
Titel project :
Verbetering van de immuuntherapeutische capaciteit van humane dendritische cellen
m.b.v. innate immuunsignalen.
Looptijd :
van
01/10/2010
tot
30/09/2013
van
van
Berneman Zwi
Smits Evelien
Promotor :
Mandaathouder :
Type Project :
30/09/2011
30/12/2011
49.475,00
Id :
24808
Onderzoeksproject
01/10/2010
01/10/2010
tot
tot
30/09/2013
30/09/2013
Fin.programma :
700300003
FWO tijdelijke mandaten: postdoct.
01/10/2010
Budget : €
Titel project :
Ontwikkeling van innovatieve methoden ter verhoging van de immuunstimulerende
werking van dendritische celtherapie voor acute myeloïde leukemie.
Looptijd :
van
01/10/2010
tot
30/09/2012
Berneman Zwi
Anguille Sébastien
Promotor :
Mandaathouder :
Type Project :
van
van
30/09/2013
224.262,00
Id :
24875
Onderzoeksproject
01/10/2010
01/10/2010
tot
tot
30/09/2012
30/09/2012
Fin.programma :
700300002
FWO tijdelijke mandaten: aspirant 1ste
hernieuwing
01/10/2010
Budget : €
Titel project :
Aanwezigheid van antibiotica-resistente pathogene bacteriën in de omgeving en de
humane comensale flora: is er een verband met ziekte?
Looptijd :
van
01/10/2010
tot
30/09/2012
Goossens Herman
Colebunders Robert
Malhotra Surbhi
Paasch Fabienne
Promotor :
Co-promotor :
Co-promotor :
Mandaathouder :
Type Project :
van
van
van
van
30/09/2012
81.176,00
Id :
25423
Onderzoeksproject
01/10/2010
01/10/2010
01/10/2010
01/10/2010
tot
tot
tot
tot
30/09/2012
30/09/2012
30/09/2012
30/09/2012
Fin.programma :
440200001
VLIR
01/10/2010
Budget : €
Titel project :
CSL Behring Leerstoel: ziekte von Willebrand.
Looptijd :
van
Promotor :
01/10/2010
tot
Berneman Zwi
30/09/2013
30/09/2012
70.950,00
Id :
Type Project :
van
25496
Onderzoeksproject
01/10/2010
tot
30/09/2013
Fin.programma :
800100114
CSL Behring
01/10/2010
Budget : €
30/09/2013
180.000,00
23/01/2012
Faculteit :
15
Departement :
Team : VAXINFECTIO
Titel project :
Analyses ter ondersteuning van de validatie van de geschatte duur van de bescherming
geboden door Havrix.
Looptijd :
van
01/12/2010
tot
31/10/2011
Van Herck Koen
Van Damme Pierre
Hens Niel
Promotor :
Co-promotor :
Co-promotor :
Type Project :
van
van
van
Id :
25686
Onderzoeksproject
tot
tot
tot
01/12/2010
01/12/2010
01/12/2010
31/10/2011
31/10/2011
31/10/2011
Fin.programma :
800100024
GlaxoSmithKline
01/12/2010
Budget : €
Titel project :
Neurale Stamcellen: moleculaire en fysiologische controle van in vivo migratie en
differentiatie.
Looptijd :
van
01/01/2011
tot
31/12/2014
Berneman Zwi
Jorens Philippe
Van Der Linden Anne Marie
Ysebaert Dirk
Ponsaerts Peter
Giugliano Michele
Pauwels Patrick
Promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Type Project :
van
van
van
van
van
van
van
31/10/2011
61.834,50
Id :
25012
Onderzoeksproject
01/01/2011
01/01/2011
01/01/2011
01/01/2011
01/01/2011
01/01/2011
01/01/2011
tot
tot
tot
tot
tot
tot
tot
31/12/2014
31/12/2014
31/12/2014
31/12/2014
31/12/2014
31/12/2014
31/12/2014
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2013
01/01/2014
01/01/2012
01/01/2011
Budget : €
Titel project :
Controle van glioblastoma door modulatie van innate immuunresponsen in de hersenen.
Looptijd :
van
Promotor :
Co-promotor :
Co-promotor :
Co-promotor :
01/01/2011
tot
31/12/2014
Berneman Zwi
Ysebaert Dirk
Ponsaerts Peter
Pauwels Patrick
Type Project :
van
van
van
van
31/12/2013
31/12/2014
31/12/2012
31/12/2011
91.056,00
Id :
25013
Onderzoeksproject
01/01/2011
01/01/2011
01/01/2011
01/01/2011
tot
tot
tot
tot
31/12/2014
31/12/2014
31/12/2014
31/12/2014
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2013
01/01/2014
01/01/2012
01/01/2011
Budget : €
31/12/2013
31/12/2014
31/12/2012
31/12/2011
100.000,00
23/01/2012
Faculteit :
16
Departement :
Team : VAXINFECTIO
Titel project :
Karakterisering van innate immuunresponsen in het centraal zenuwstelsel: modulatie tot
immunologische acceptatie van allogene celimplantaten.
Looptijd :
van
01/01/2011
tot
31/12/2014
Berneman Zwi
Van Der Linden Anne Marie
Ysebaert Dirk
Ponsaerts Peter
Pauwels Patrick
Promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Type Project :
van
van
van
van
van
Id :
25014
Onderzoeksproject
01/01/2011
01/01/2011
01/01/2011
01/01/2011
01/01/2011
tot
tot
tot
tot
tot
31/12/2014
31/12/2014
31/12/2014
31/12/2014
31/12/2014
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2013
01/01/2014
01/01/2012
01/01/2011
Budget : €
Titel project :
Efficiëntie, billijkheid en autonomie: de ethiek van een vaccinatiebeleid.
Looptijd :
van
01/01/2011
tot
31/12/2014
Beutels Philippe
Van Damme Pierre
Promotor :
Co-promotor :
Type Project :
van
van
31/12/2013
31/12/2014
31/12/2012
31/12/2011
140.000,00
Id :
25106
Onderzoeksproject
01/01/2011
01/01/2011
tot
tot
31/12/2014
31/12/2014
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2013
01/01/2014
01/01/2012
01/01/2011
Budget : €
Titel project :
Karakterisatie van het naso-oro-pharyngeale microbioom en resistoom in de Europese
populatie.
Looptijd :
van
01/01/2011
tot
31/12/2013
Goossens Herman
Malhotra Surbhi
Promotor :
Co-promotor :
Type Project :
van
van
31/12/2013
31/12/2014
31/12/2012
31/12/2011
240.000,00
Id :
25156
Onderzoeksproject
01/01/2011
01/01/2011
tot
tot
31/12/2013
31/12/2013
Fin.programma :
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2013
01/01/2012
01/01/2011
Budget : €
200.000,00
Titel project :
Immuunmodulerende therapie voor ruggenmergletsels gebruikmakende van IL-4 en IL-13
producerende celtransplanten.
Looptijd :
van
Promotor :
01/01/2011
tot
31/12/2014
Ponsaerts Peter
Type Project :
van
31/12/2013
31/12/2012
31/12/2011
Id :
25176
Onderzoeksproject
01/01/2011
tot
31/12/2014
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2013
01/01/2014
01/01/2012
01/01/2011
Budget : €
31/12/2013
31/12/2014
31/12/2012
31/12/2011
45.528,00
23/01/2012
Faculteit :
17
Departement :
Team : VAXINFECTIO
Titel project :
Boosting the cross-talk between human dendritic cells and natural killer cells by Toll -like
receptor-ligand-loaded leukemia cells for optimal anti- leukemia T cell responses.
Looptijd :
van
01/01/2011
tot
31/12/2011
Type Project :
van
Promotor :
Id :
25411
Onderzoeksproject
tot
01/01/2011
31/12/2011
Fin.programma :
800300042
Vlaamse Liga tegen Kanker
01/01/2011
Budget : €
Titel project :
Inductie van multiple sclerose (MS)-specifieke immuuntolerantie gebruikmakende van
tolerogene dendritische cellen en regulerende T -cellen. Preklinische evaluatie van het
therapeutisch potentieel van cellulaire immuuntherapie bij MS.
Looptijd :
van
01/01/2011
tot
31/12/2012
Type Project :
van
van
Nuyts Amber
Promotor :
Mandaathouder :
31/12/2011
60.000,00
Id :
25730
Onderzoeksproject
tot
tot
01/01/2011
01/01/2011
31/12/2012
31/12/2012
Fin.programma :
550400002
IWT strategische onderzoeksbeurs - tweede
termijn
01/01/2011
Budget : €
Titel project :
Boosting the cross-talk between human dentritic cells and natural killer cells by Toll -like
receptor ligand-loaded leukemia cells for optimal anti- leukemia T cell responses.
Looptijd :
van
01/01/2011
tot
31/12/2012
Type Project :
van
Promotor :
31/12/2012
82.775,00
Id :
25828
Onderzoeksproject
tot
01/01/2011
31/12/2012
Fin.programma :
800400004
Stichting tegen Kanker (voorheen Belg. Fed.
tegen Kanker)
01/01/2011
Budget : €
Titel project :
Feasibility and safety of a WT1-targeted cancer vaccine in patients with malignant
mesothelioma and locally advanced breast cancer: an open label phase I trial.
Looptijd :
van
Promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Co-promotor :
01/01/2011
tot
31/12/2013
Type Project :
Berneman Zwi
Germonpre Paul
Van Schil Paul
Van de Velde Ann
Peeters Marc
Huizing Manon
van
van
van
van
van
van
van
31/12/2012
125.000,00
Id :
25866
Onderzoeksproject
01/01/2011
01/01/2011
01/01/2011
01/01/2011
01/01/2011
01/01/2011
01/01/2011
tot
tot
tot
tot
tot
tot
tot
31/12/2013
31/12/2013
31/12/2013
31/12/2013
31/12/2013
31/12/2013
31/12/2013
Fin.programma :
800400004
Stichting tegen Kanker (voorheen Belg. Fed.
tegen Kanker)
01/01/2011
Budget : €
31/12/2013
241.000,00
23/01/2012
Faculteit :
18
Departement :
Team : VAXINFECTIO
Titel project :
The immune-modulating role of vitamin D3-treated dendritric cells in multiple sclerosis.
Looptijd :
van
01/01/2011
tot
31/12/2013
Cools Nathalie
Promotor :
Co-promotor :
Type Project :
van
van
Id :
26444
Onderzoeksproject
01/01/2011
01/01/2011
tot
tot
31/12/2013
31/12/2013
Fin.programma :
800400026
Charcot Stichting
01/01/2011
31/12/2013
Budget : €
Titel project :
Development of Rapid Point-of-Care test Platforms for Infectious Diseases (RAPP-ID).
Looptijd :
van
01/01/2011
tot
31/12/2015
Goossens Herman
Promotor :
Type Project :
van
39.000,00
Id :
26553
Onderzoeksproject
01/01/2011
tot
31/12/2015
Fin.programma :
3701
EU KP7: Gezondheid
01/01/2011
Budget : €
Titel project :
Prioritisering van de doelgroepen met betrekking tot de vaccinatie voor seizoensgriep deel 2.
Looptijd :
van
15/01/2011
tot
30/01/2012
Beutels Philippe
Promotor :
Type Project :
van
31/12/2015
1.390.684,70
Id :
25890
Onderzoeksproject
15/01/2011
tot
30/01/2012
Fin.programma :
459900003
15/01/2011
Budget : €
204.490,00
Titel project :
Development of Module for the Immunological Basis for Immunization Series on Hepatitis
B.
Looptijd :
van
31/01/2011
tot
04/02/2011
Van Damme Pierre
Promotor :
Type Project :
van
30/01/2012
Id :
26176
Onderzoeksproject
31/01/2011
tot
04/02/2011
Fin.programma :
3952
WGO (Wereldgezondheidsorganisatie)
31/01/2011
Budget : €
2.384,20
Titel project :
A randomized, double-blinded, controlled with Gardasil® (Human Papillomavirus Vaccine)
Phase III clinical trial to study the immunogenicity and tolerability of V503 in preadolescent
and adolescent girls.
Looptijd :
van
Promotor :
01/03/2011
tot
30/04/2012
Van Damme Pierre
Type Project :
van
04/02/2011
Id :
26185
Onderzoeksproject
01/03/2011
tot
30/04/2012
Fin.programma :
302100054
Sanofi Pasteur MSD
01/03/2011
Budget : €
30/04/2012
114.554,00
23/01/2012
Faculteit :
19
Departement :
Team : VAXINFECTIO
Titel project :
A randomized, double-blinded, controlled with Gardasil, Phase III clinical trial to study the
immunogenicity and tolerability of V503 in preadolescent and adolescent girls (9 to
15-years-olds).
Looptijd :
van
01/03/2011
tot
28/02/2012
Van Damme Pierre
Promotor :
Type Project :
van
Id :
26186
Onderzoeksproject
01/03/2011
tot
28/02/2012
Fin.programma :
302100054
Sanofi Pasteur MSD
01/03/2011
Budget : €
4.000,00
Titel project :
A phase 1/2, randomized, open-label, study to assesss the immunogenicity and safety of
a vaccine enhancement patch (vep) when administered with two doses of intramuscular
inactivated influenza h5n1 vaccine in healthy adults.
Looptijd :
van
16/03/2011
tot
31/12/2012
Van Damme Pierre
Promotor :
Type Project :
van
28/02/2012
Id :
26336
Onderzoeksproject
16/03/2011
tot
31/12/2012
Fin.programma :
302100088
Intercell
16/03/2011
31/12/2012
Budget : €
0,00
Titel project :
Long-term follow up study of a GSK Biologicals' recombinant CMV gB sub-unit vaccine in
SMV-seronegative healthy male adults vaccinated in the Phase 1, study CMV-001 and
having participated in the follow-up study.
Looptijd :
van
01/05/2011
tot
30/09/2012
Van Damme Pierre
Promotor :
Type Project :
van
Id :
26488
Onderzoeksproject
01/05/2011
tot
30/09/2012
Fin.programma :
800100024
GlaxoSmithKline
01/05/2011
Budget : €
Titel project :
Development and implementation of a curriculum for an interactive training course on
vaccinology.
Looptijd :
van
27/05/2011
tot
15/08/2011
Van Damme Pierre
Promotor :
Type Project :
van
30/09/2012
5.040,00
Id :
26504
Onderzoeksproject
27/05/2011
tot
15/08/2011
Fin.programma :
3952
WGO (Wereldgezondheidsorganisatie)
27/05/2011
Budget : €
Titel project :
Translational research on antimicrobial resistance and community -acquired infections in
Europe (TRACE).
Looptijd :
van
16/06/2011
tot
15/06/2016
Goossens Herman
Coenen Samuel
Promotor :
Co-promotor :
Type Project :
van
van
15/08/2011
34.712,99
Id :
26771
Onderzoeksproject
16/06/2011
16/06/2011
tot
tot
15/06/2016
15/06/2016
Fin.programma :
3914
ESF
16/06/2011
Budget : €
15/06/2016
12.500,00
23/01/2012
Faculteit :
20
Departement :
Team : VAXINFECTIO
Titel project :
Ontwikkelen en optimaliseren van stochastische individu-gebaseerde simulatiemodellen
door middel van parallelle multicore rekentechnieken.
Looptijd :
van
01/07/2011
tot
30/06/2013
Beutels Philippe
Broeckhove Jan
Hens Niel
Promotor :
Co-promotor :
Co-promotor :
Type Project :
van
van
van
Id :
25759
Onderzoeksproject
01/07/2011
01/07/2011
01/07/2011
tot
tot
tot
30/06/2013
30/06/2013
30/06/2013
Fin.programma :
541200021
BOF: Interdisciplinaire doctoraatsbeurzen
01/07/2011
Budget : €
90.000,00
Titel project :
An exploration of the moral relevance of medical effectiveness and intangible costs for the
societal valuation of QALY-Gains.
Looptijd :
van
15/07/2011
tot
14/07/2012
Beutels Philippe
Promotor :
Type Project :
van
30/06/2013
Id :
26555
Onderzoeksproject
15/07/2011
tot
14/07/2012
Fin.programma :
800100045
Pfizer
15/07/2011
Budget : €
40.000,00
Titel project :
ABC-RBOD A Retrospective Study to Assess the Clinical Burden of Hospitalized
Community-Acquired Pneumonia (CAP) in Adults in Belgium volgens het Specific
Statistical Analysis Plan (S - SAP) van 23 februari 2010 (uitvoering CARENET-database).
Looptijd :
van
15/07/2011
tot
01/12/2011
van
Hens Niel
Promotor :
Type Project :
14/07/2012
Id :
26600
Onderzoeksproject
15/07/2011
tot
01/12/2011
Fin.programma :
800100045
Pfizer
15/07/2011
Budget : €
Titel project :
Tolerance and Immunogenicity of ProCervix, an adjuvanted therapeutic vaccine
Looptijd :
van
Promotor :
21/07/2011
tot
24/05/2012
Van Damme Pierre
Type Project :
van
01/12/2011
1.449,00
Id :
25291
Onderzoeksproject
21/07/2011
tot
24/05/2012
Fin.programma :
302100080
Genticel
21/07/2011
Budget : €
24/05/2012
181.611,57
23/01/2012
Faculteit :
21
Departement :
Team : VAXINFECTIO
Titel project :
In vivo identificatie en validatie van immuun-onderdrukkende signaaltransductie proteïnen
en/of receptoren betrokken in glioblastoma-geïnduceerde inhibitie van microglia.
Looptijd :
van
01/10/2011
tot
30/09/2015
Type Project :
van
van
van
Berneman Zwi
Ponsaerts Peter
Hoornaert Chloé
Promotor :
Co-promotor :
Mandaathouder :
Id :
25839
Onderzoeksproject
tot
tot
tot
01/10/2011
01/10/2011
01/10/2011
30/09/2015
30/09/2015
30/09/2013
Fin.programma :
800000028
Legaten
01/10/2011
Budget : €
Titel project :
Een kwantitatieve analyse van varicella-zoster virus infectie: van immunologie tot
epidemiologie.
Looptijd :
van
01/10/2011
tot
30/09/2013
Type Project :
van
van
van
van
Beutels Philippe
Van Damme Pierre
Ogunjimi Benson
Promotor :
Co-promotor :
Co-promotor :
Mandaathouder :
30/09/2013
160.000,00
Id :
25992
Onderzoeksproject
01/10/2011
01/10/2011
01/10/2011
01/10/2011
tot
tot
tot
tot
30/09/2013
30/09/2013
30/09/2013
30/09/2013
Fin.programma :
700300001
FWO tijdelijke mandaten: aspirant
01/10/2011
Budget : €
Titel project :
Onderzoek in het domein van de medische microbiologie.
Looptijd :
van
01/10/2011
tot
30/09/2014
Malhotra Surbhi
Malhotra Surbhi
Promotor :
Mandaathouder :
30/09/2013
80.644,00
Id :
Type Project :
van
van
26657
Onderzoeksproject
01/10/2011
01/10/2011
tot
tot
30/09/2014
30/09/2014
Fin.programma :
5413
ZAP BOF-mandaten
01/10/2011
Budget : €
Titel project :
Resistance in gram-negative organisms: studying intervention strategies (R-GNOSIS).
Looptijd :
van
Promotor :
Co-promotor :
01/10/2011
tot
30/09/2016
Goossens Herman
Malhotra Surbhi
Type Project :
van
van
30/09/2014
255.000,00
Id :
26776
Onderzoeksproject
01/10/2011
01/10/2011
tot
tot
30/09/2016
30/09/2016
Fin.programma :
3701
EU KP7: Gezondheid
01/10/2011
Budget : €
30/09/2016
847.490,00
23/01/2012
Faculteit :
22
Departement :
Team : VAXINFECTIO
Titel project :
Preklinische ontwikkeling van een geoptimaliseerd dendritische cel-gebaseerd vaccin
tegen acute myeloïde leukemie.
Looptijd :
van
15/11/2011
tot
31/12/2012
Type Project :
van
Anguille Sébastien
Promotor :
Id :
26649
Onderzoeksproject
15/11/2011
tot
31/12/2012
Fin.programma :
800400018
jonge vorsers
15/11/2011
Budget : €
Titel project :
De kwantitatieve analyse van de varicella-zoster-virus infectie: van epidemiologie tot
immunologie.
Looptijd :
van
15/11/2011
tot
31/12/2012
Type Project :
van
Ogunjimi Benson
Promotor :
31/12/2012
2.500,00
Id :
26652
Onderzoeksproject
15/11/2011
tot
31/12/2012
Fin.programma :
800400018
jonge vorsers
15/11/2011
Budget : €
Titel project :
Onderzoek naar vaccinatietoestand bij darminvaginatie voorkomend tijdens het eerste
levensjaar.
Looptijd :
van
15/11/2011
tot
31/12/2011
Type Project :
van
van
Beutels Philippe
Hens Niel
Promotor :
Co-promotor :
31/12/2012
2.500,00
Id :
26899
Onderzoeksproject
15/11/2011
15/11/2011
tot
tot
31/12/2011
31/12/2011
Fin.programma :
459900008
Federaal Agentschap voor Geneesmiddelen en
Gezondheidsproducten (FAGG)
15/11/2011
Budget : €
Titel project :
Onderzoek naar de mogelijke associatie tussen toediening van het Pandemrix vaccin en
Guillain-Barré syndrome (GBS).
Looptijd :
van
Promotor :
Co-promotor :
15/12/2011
tot
14/12/2012
Type Project :
Beutels Philippe
Hens Niel
van
van
31/12/2011
10.000,00
Id :
26900
Onderzoeksproject
15/12/2011
15/12/2011
tot
tot
14/12/2012
14/12/2012
Fin.programma :
459900008
Federaal Agentschap voor Geneesmiddelen en
Gezondheidsproducten (FAGG)
15/12/2011
Budget : €
14/12/2012
25.000,00
23/01/2012
Faculteit :
23
Departement :
Team : VAXINFECTIO
Titel project :
Kwantificering van varicella-zoster virus boosting mechanismes met hun
volksgezondheidsimplicaties voor vaccinatie.
Looptijd :
van
01/01/2012
tot
31/12/2014
Beutels Philippe
Van Damme Pierre
Smits Evelien
Hens Niel
Promotor :
Co-promotor :
Co-promotor :
Co-promotor :
Type Project :
van
van
van
van
Id :
26227
Onderzoeksproject
01/01/2012
01/01/2012
01/01/2012
01/01/2012
tot
tot
tot
tot
31/12/2014
31/12/2014
31/12/2014
31/12/2014
Fin.programma :
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2013
01/01/2014
01/01/2012
Budget : €
Titel project :
MSC/MAPC-gebaseerde modulatie van immuun/inflammatorische mechanismen bij
beenmergfalen in MDS.
Looptijd :
van
01/01/2012
tot
31/12/2013
van
Berneman Zwi
Promotor :
Type Project :
31/12/2013
31/12/2014
31/12/2012
143.000,00
Id :
26242
Onderzoeksproject
01/01/2012
tot
31/12/2013
Fin.programma :
7403
7403
FWO Kom op tegen Kanker
FWO Kom op tegen Kanker
01/01/2013
01/01/2012
Budget : €
Titel project :
T cel immunogeniciteit van RHAMM en BMI-1: ontwikkeling van een multi-antigenisch
dendritisch celvaccin voor hematologische maligniteiten.
Looptijd :
van
01/01/2012
tot
31/12/2015
Berneman Zwi
Smits Evelien
Promotor :
Co-promotor :
Co-promotor :
Type Project :
van
van
van
31/12/2013
31/12/2012
180.000,00
Id :
26312
Onderzoeksproject
01/01/2012
01/01/2012
01/01/2012
tot
tot
tot
31/12/2015
31/12/2015
31/12/2015
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2013
01/01/2014
01/01/2015
01/01/2012
Budget : €
Titel project :
Karakteriseren van gastheer-pathogeen interacties en biofilmvorming bij patiënten met
ventilator-geassocieerde pneumonie.
Looptijd :
van
Promotor :
Co-promotor :
Co-promotor :
01/01/2012
tot
31/12/2015
Goossens Herman
Kumar-Singh Samir
Malhotra Surbhi
Type Project :
van
van
van
31/12/2013
31/12/2014
31/12/2015
31/12/2012
200.000,00
Id :
26349
Onderzoeksproject
01/01/2012
01/01/2012
01/01/2012
tot
tot
tot
31/12/2015
31/12/2015
31/12/2015
Fin.programma :
7010
7010
7010
7010
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
FWO Groepsprojecten
01/01/2013
01/01/2014
01/01/2015
01/01/2012
Budget : €
31/12/2013
31/12/2014
31/12/2015
31/12/2012
200.000,00
23/01/2012
Faculteit :
24
Departement :
Team : VAXINFECTIO
Titel project :
Methicilline-resistente Staphylococcus aureus: Verkenning van de 'biofilmome' voor
markers van infectie.
Looptijd :
van
01/01/2012
tot
31/12/2014
Malhotra Surbhi
Promotor :
Type Project :
van
Id :
26436
Onderzoeksproject
01/01/2012
tot
31/12/2014
Fin.programma :
7020
01/01/2012
Budget : €
25.000,00
Titel project :
In vivo niet-invasieve beeldvorming van immunotherapie voor acute myeloide leukemie in
een muismodel.
Looptijd :
van
01/01/2012
tot
31/12/2014
van
Smits Evelien
Promotor :
Type Project :
31/12/2014
Id :
26437
Onderzoeksproject
01/01/2012
tot
31/12/2014
Fin.programma :
7020
01/01/2012
Budget : €
Titel project :
Reducing the burden of Pertussis disease in very young infants in different
epidemiological settings through pertussis vaccination in pregnancy.
Looptijd :
van
01/01/2012
tot
31/12/2013
Van Damme Pierre
Promotor :
Type Project :
van
31/12/2014
20.000,00
Id :
26800
Onderzoeksproject
01/01/2012
tot
31/12/2013
Fin.programma :
7499
7499
Andere middelen beheerd door het FWO
Andere middelen beheerd door het FWO
01/01/2013
01/01/2012
Budget : €
Titel project :
iTRACE.
Looptijd :
van
128.817,00
Id :
01/01/2012
tot
31/12/2014
Goossens Herman
Promotor :
31/12/2013
31/12/2012
Type Project :
van
26828
Onderzoeksproject
01/01/2012
tot
31/12/2014
Fin.programma :
749900002
749900002
749900002
FWO-Internationale Coördinatieactie
01/01/2012
01/01/2013
01/01/2014
Budget : €
Titel project :
BOF/IWT-opvangmandaat.
Looptijd :
van
Promotor :
Mandaathouder :
01/01/2012
tot
31/12/2012
31/12/2013
31/12/2014
225.000,00
Id :
31/12/2012
Deckx Nathalie
Type Project :
van
van
26908
Onderzoeksproject
01/01/2012
01/01/2012
tot
tot
31/12/2012
31/12/2012
Fin.programma :
541200004
BOF: Opvangmandaten IWT
01/01/2012
Budget : €
31/12/2012
36.500,00
23/01/2012
Faculteit :
25
Departement :
Team : VAXINFECTIO
Titel project :
RHAMM and BMI1 as attractive immunotherapeutic target antigens for the development
and optimization of a clinical grade multi-antigenic dendritic cell vaccine against leukemia
and myeloma.
Looptijd :
van
01/01/2012
tot
31/12/2013
Type Project :
van
van
Berneman Zwi
Willemen Yannick
Promotor :
Mandaathouder :
Id :
26964
Onderzoeksproject
01/01/2012
01/01/2012
tot
tot
31/12/2013
31/12/2013
Fin.programma :
550400001
IWT strategische onderzoeksbeurs - eerste
termijn
01/01/2012
31/12/2013
Budget : €
Titel project :
Tolerogene dendritische cellen: ontwikkeling van een "negatief" cellulair vaccin voor de
behandeling van auto-immuniteit.
Looptijd :
van
01/01/2012
tot
31/12/2013
Type Project :
van
van
Berneman Zwi
Lee Wai Ping
Promotor :
Mandaathouder :
83.085,00
Id :
26973
Onderzoeksproject
01/01/2012
01/01/2012
tot
tot
31/12/2013
31/12/2013
Fin.programma :
550400001
IWT strategische onderzoeksbeurs - eerste
termijn
01/01/2012
31/12/2013
Budget : €
Titel project :
Studie naar de vaccinatiegraad in Vlaanderen in 2012.
Looptijd :
van
Promotor :
04/01/2012
tot
31/12/2012
Id :
Type Project :
Van Damme Pierre
83.085,00
van
26966
Onderzoeksproject
04/01/2012
tot
31/12/2012
Fin.programma :
5104
Departement Welzijn, Volksgezondheid en
Cultuur
04/01/2012
Budget : €
VAXINFECTIO
aantal projecten :
Totaal budget : €
Totaal budget : €
31/12/2012
274.787,28
105
28.630.971,43
28.630.971,43
Lopende Projecten Censtat 2011 met Eng. titel
G2
PROJ_NR PROJ_BEGINDAT PROJ_EINDDAT CONTRACTSOORT
BENAMING
R‐1248
R‐1327
R‐1330
R‐1343
R‐1432
R‐1494
R‐1504
R‐1617
R‐1617
R‐1829
R‐2085
R‐2088
R‐2897
R‐2964
R‐3159
R‐3160
R‐3778
IUAP ‐ STADEC
BOF ‐ doctoraatsbursaal : Yovanna Castro Sanchez Amparro
BOF 08 ‐ Methusalem‐project : Vaxinfectio ‐ Molenberghs
IOF‐mandaat oproep 2008 : Herbert Thijs
FWO onderzoeksproject ‐ Molenberghs
BOF09‐Groot project
BOF09: nieuw initiatief
IUAP ‐ Phase VI:European Partnership Contract onder R‐1248
IUAP ‐ Phase VI:European Partnership Contract onder R‐1248
BOF2009: doctoraatsbeurs Yves Grouwels
FWO‐onderzoeksovereenkomst Aerts Marc
FWO‐onderzoeksproject Christel Faes
BOF nieuw initiatief BOF11 ‐ NI 31
BOF Kort verblijf dr. James Wood
BOF Doctoraat Vandendijck Yannick
BOF Doctoraat Martin Otava
WOG Geert Molenberghs
01.01.2007
01.10.2008
01.01.2008
01.01.2009
01.01.2009
01.01.2009
01.01.2009
01.01.2007
01.01.2007
01.10.2009
01.01.2010
01.01.2010
01.01.2011
11.04.2011
01.10.2011
01.10.2011
01.01.2011
31.03.2012
30.09.2011
31.12.2014
31.12.2013
31.12.2012
31.12.2012
31.12.2012
31.12.2011
31.12.2011
30.09.2011
31.12.2013
31.12.2013
31.12.2014
11.06.2011
30.09.2015
30.09.2015
31.12.2015
Vernieuwend Contractonderzoek
G3
BENAMING
R‐1175
R‐1272
R‐1942
01.03.2007
01.01.2007
01.04.2009
31.12.2011
31.12.2011
31.03.2011
IWT ‐ SBO ‐ SIMID
Steunpunt Milieu en Gezondheid
VLIR‐UOS agreement
R‐2121
16.12.2009
15.03.2011
Europees Project EFSA ‐ Zoonoses 4
R‐2345
R‐2373
01.07.2009
01.09.2009
30.06.2011
31.08.2011
ECDC‐project grant 2009/002
Subaward agreement WFUHS
R‐2679
15.05.2010
31.10.2011
Stand wet. dienstverlening
Dienstverleningsovereenkomst CENSTAT ‐ University of Marburg
R‐2722
R‐2910
R‐2917
R‐3080
R‐3122
R‐3157
01.10.2011
01.01.2011
15.01.2011
01.10.2010
16.05.2011
01.04.2011
30.09.2015
31.12.2011
31.01.2012
31.12.2011
15.06.2011
31.03.2013
Samenwerking Censtat‐VITO doctoraat Burzykowski
Personeelsdatabank 2011
KCE‐studie : Censtat en UA
VLIR‐UOS: Biostatistiek
Dienstverleningsovereenkomst WET_O_179664‐BRUL
VLIR‐project Ziv Shkedy Oost‐ en Zuidelijk Afrika
R‐3279
R‐3321
R‐3325
19.07.2011
22.09.2011
01.04.2011
18.07.2012
21.10.2011
30.09.2011
EFSA call BIOMI/02
Dienstverleningsovereenkomst WET_O_182106‐MOLG
Consultancy Agreement SERVIER
G4
BENAMING
R‐1066
R‐1186
R‐1360
R‐1398
R‐1949
R‐2584
R‐2850
R‐2946
R‐3016
R‐3017
01.01.2005
01.01.2007
01.07.2008
01.07.2008
01.05.2009
07.07.2010
01.01.2011
08.02.2011
21.03.2011
21.03.2011
31.12.2011
31.12.2011
31.12.2011
31.07.2011
31.12.2011
06.07.2011
31.12.2013
07.03.2011
20.04.2011
20.04.2011
Biostatistische consulting
Wetenschappelijke dienstverlening ‐ SPIL
Commitee member agreement
Dienstverlening
Wetenschappelijke Dienstverlening
Verlenging Consultancy Master Agreement R‐1352/R‐1911
Dienstenovereenkomst met GSK Biologicals
Werkstaat onder V‐778 / dienstverleningsovereenkomst WET‐176273
Dienstverleningsovereenkomst WET_O_178390_MOLG
Dienstverleningsovereenkomst WET_O_178392_MOLG
R‐3038
R‐3040
R‐3069
R‐3126
R‐3129
R‐3134
R‐3137
01.01.2011
23.02.2011
01.10.2010
01.06.2011
01.01.2011
09.05.2011
19.05.2011
31.12.2011
30.06.2011
30.09.2011
31.05.2013
30.03.2012
08.05.2014
18.06.2011
Onderaanneming Jessa Ziekenhuis 2011
Work Order onder V‐789
Francqui leerstoel prof. Davison
Framework Agreement Censtat ‐ Mars
Work order onder duurovereenkomst met Sanofi‐Aventis
Consultancy agreement met Metronic
Dienstverleningsovereenkomst WET_O_179808‐THIH
R‐3154
R‐3199
01.02.2011
27.06.2011
31.07.2012
26.07.2011
IWT KMO‐innovatieproject Censtat ‐ Thalento
dienstverlening onder duurovereenkomst V‐655
R‐3219
R‐3270
R‐3271
R‐3272
R‐3275
R‐3281
R‐3283
R‐3286
01.07.2011
02.08.2011
27.06.2011
14.07.2011
01.09.2011
11.08.2011
01.04.2011
04.03.2011
30.06.2015
01.09.2011
26.07.2011
31.10.2011
31.08.2013
10.09.2011
30.06.2011
30.03.2012
samenwerkingsovereenkomst Janssen Pharmaceutica Doreen Abaine
Work Assignment onder V‐789
AXA Postdoc Nele Goeyvaerts
Work order onder consultancy agr. met Shire‐Movetis
Work order 2 onder duurovereenkomst met Sanofi‐Aventis
R‐3332
R‐3355
15.09.2011
01.06.2011
14.09.2015
31.12.2011
Doctoraat Leandro Garcia Barrado met IDDI
Work order 2 onder consultancy agr. met Shire‐Movetis
R‐3390
R‐3392
R‐3468
R‐3662
R‐3664
01.10.2011
04.10.2011
04.10.2011
29.11.2011
19.12.2011
30.09.2015
03.11.2011
03.11.2011
28.12.2011
18.01.2012
Doctoraat Sammy Chebon
PROJ_TOTBEDRAG ICO_PROMOTOR
400,000.00
146,000.00
980,000.00
194,678.00
138,800.00
494,700.00
174,900.00
25,000.00
25,000.00
162,500.00
100,000.00
272,000.00
180,000.00
4,660.00
162,500.00
162,500.00
4,460.00
VERAVERBEKE Noel
AERTS Marc
MOLENBERGHS Geert
AERTS Marc
MOLENBERGHS Geert
MOLENBERGHS Geert
BURZYKOWSKI Tomasz
AERTS Marc
VERAVERBEKE Noel
BRAEKERS Roel
AERTS Marc
FAES Christel
HENS Niel
HENS Niel
FAES Christel
SHKEDY Ziv
MOLENBERGHS Geert
615,000.00 AERTS Marc
79,700.00 MOLENBERGHS Geert
58,443.00 SHKEDY Ziv
16,200.00 SHKEDY Ziv
TITEL
Statistical analysis of association and dependence in complex data
Mathematical and Statistical Models for HIV and Co‐Infections
VAXINFECTIO to suppress and prevent zymotic diseases
Coordination of scientific services and contract research.
A flexible method for modelling non‐normal hierarchical data structures
A Powerful Modeling Framework for Efficient Design and Analysis of Life Sciences Studies
Statistical analysis of isotope‐labeled MALDI‐TOF mass spectra
Zero‐inflated semi‐parametric Cox┌s regression models for le ‐censored mul variate survival data.
Data‐driven modelling of the impact of early, wide‐scale HIV treatment on HIV incidence in Southern Africa
Spatio‐temporal modeling of infectious diseases
Modelling epidemics using new statistical methodology based on network data and incomplete data methodology.
Estimating vaccination coverage from trivariate serological data and incidence data.
Statistical methods for the analysis of surveys with an informative spatio‐temporal sampling design.
Modeling Dose‐Response Microarray Data Using Bayesian Variable Selection (BVS) Methods
historical demography
TITEL
Simulation models of infectious disease transmission and control processes (SIMID), with applications to five major health policy issues in Flanders
Environment and health
/
Request for assistance in development of statistical analyses of methods for evaluation of data on antimicrobial resistance in zoonotic agent isolates from animals and food.
Consortium Agreement concerning the EDCD‐prject: "VACCINE PREVENTABLE DISEASES MODELLING IN THE EUROPEAN UNION AND EEA/EFTA COUNTRIES: FORECASTING TNHE EFFECT OF INTRODUCING A NEW VACCINE IN A NATIONAL/REGIONAL PROGRAM"
Longitudinal methods for complex interactions in elderly populations.
Coronary heart disease in primary care: the accuracy of the history and physical findings. A systematic review with individual patient data.
183,169.85
7,450.00
33,800.00
259,418.00
9,000.00
122,821.00
BURZYKOWSKI Tomasz
AERTS Marc
HENS Niel
JANSSEN Paul
BRUCKERS Liesbeth
SHKEDY Ziv
413.22 MOLENBERGHS Geert
41,430.00
40,000.00
11,157.02
11,875.00
52,742.62
10,000.00
113,256.00
1,050.00
450.00
545.00
MOLENBERGHS Geert
MOLENBERGHS Geert
MOLENBERGHS Geert
THIJS Herbert
MOLENBERGHS Geert
AERTS Marc
SHKEDY Ziv
HENS Niel
MOLENBERGHS Geert
MOLENBERGHS Geert
26,860.00
5,400.00
6,000.00
200,000.00
28,750.00
14,850.00
600.00
AERTS Marc
MOLENBERGHS Geert
JANSSEN Paul
THIJS Herbert
MOLENBERGHS Geert
THIJS Herbert
THIJS Herbert
26,000.00 THIJS Herbert
190.00 MOLENBERGHS Geert
Coorporation agreement within the framework of the PhD: "Novel informatics algorithms for the analysis of post‐translational modifications in mass spectrometry data"
Personal Database
Determination of target groups that should receive priority for seasonal influenza vaccination
International course "Master of Science in Biostatistics"
Environmental Health Survey of South Limburg
Capacity construction Statistics, with pilot region Eastern and Southern Africa
Analysing and reporting data on multi‐resistance in antimicrobial resistance isolate based data collected from volunteer Member States for the year 2010.
Evaluation epidemiological study of possible health effects of living near nuclear site in Belgium
Consultancy Agreement
TITEL
Biostatistical consulting
Creation MPG‐ unity files
Committee member agreement
DATASAFETY MONITORING BOARD
Consulting Agreement
Continuation of Consultancy services under the terms of our agreement Dated 7the July, 2008.
Agreement for R&D Services
Statistical services for September, October and November 2010
In house consulting January 2011
In house consulting December 2010
Subcontracting Contract: Policy Information on psychiatric services and settings: continuous recording of clinical and social variables / Agreement on the support of registration: 'Minimum Psychiatric Data' 2011 "
Work assignment for consultancy services
Francqui Chair prof. Christopher Davison
Framework agreement : statistical advisory core and statistical consultancy services
Work order no 1 , under the master consultancy agreement V‐793
Consulting agreement between the University of Hasselt and Metronic International
Cox models vs Poisson regression
Matching people and organization: statistical modeling and psychometric research for the identification and objectification of the professional environment as part of the selection, development and management of an employee
In house consulting March 2011
149,381.01 BURZYKOWSKI Tomasz
Cooperation between CenStat and Janssen Pharmaceutica in connection with the doctorate from Doreen Abainenamar.
Checking the accuracy of the data from the files of students count on May 13, 2011
EAZY registry ‐ Statistical advice concerning sample size calculations
Overall statistical activities as specified in the Consultancy Agreement V‐789
Post‐doctoral sponsorship agreement
Welfare Research Beerse
Statement of work 1
Work order 2 under the framework agreement V‐793
Collaboration agreement with IDDI concerning the doctoral of Leandro Garcia Barrado with titel "Bayesian statistics and Bioinformatics for Biomarker validation using Biobanks in Alzheimer's Disease (B4AD)"
Statement of work 2 under the consultancy agreement with Shire‐Movetis (V‐798)
199,174.68
6,587.50
6,750.00
1,150.00
6,930.00
Collaboration agreement between Censtat en Janssen Pharmaceutica concerning the doctoral of Sammy Chebon with titel " Increasing the efficiency of future toxicology studies through the development of innovative statistical approaches"
TURP study ‐ data analysis
Switch Study
Statistical processing visionary study
Interpret Study
199,174.68
1,818.20
800.00
6,480.00
120,000.00
3,200.00
3,000.00
39,980.00
MOLENBERGHS Geert
BRUCKERS Liesbeth
THIJS Herbert
MOLENBERGHS Geert
HENS Niel
BRUCKERS Liesbeth
MOLENBERGHS Geert
THIJS Herbert
FAES Christel
BRUCKERS Liesbeth
THIJS Herbert
BRUCKERS Liesbeth
THIJS Herbert

Methusalem Report 2011

Transcription

Similar documents

DUTCH BURGHER UNION. . 76 GENEALOGY OF THE FAMILY OF

middeleeuws spektakel in begijnhof filosofie in

Bloedbeeld nr. 3, december 2015

navorsingsverslag research report - WWW0

navorsingsverslag research report - WWW0